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Abstract 
Within the context of health system strengthening and pharmaceutical systems development goals, a 
population must have equitable access to quality affordable medicines and pharmaceutical supplies. The 
utilization of the private (for-profit and not-for-profit) pharmaceutical sector actors by the public to promote 
universal access to quality medicines and related commodities is an increasingly common practice in resource 
poor settings. Faith-based drug supply organizations (FB-DSOs), as a component of the private-not-for-profit 
(PNFP) sector, are increasingly involved in the supply of pharmaceuticals to complement public sector efforts 
in wider coverage of communities in Africa. However, their role in the pharmaceutical system in Africa is not 
well defined. This paper presents the results of a systematic review conducted to map out the organization of 
pharmaceutical systems and establish the role of faith-based health care providers in the pharmaceutical 
supply chain in Africa.  
For this study, a scoping review was first conducted to map the literature on pharmaceutical supply chains in 
low- and middle-income countries (LMICs), understand the challenges facing pharmaceutical supply chains in 
LMICs and the role faith-based health care providers play in the pharmaceutical supply chain. After this, a 
qualitative systematic review was conducted across multiple electronic databases to identify documents that 
contain information on faith-based involvement in pharmaceutical supply chain in Africa. Citation tracking was 
used to identify further relevant articles. Included materials were analyzed using thematic narrative analysis 
and synthesized.  
The public pharmaceutical supply chain in Africa is faced with challenges including drug stock outs and 
irregular supplies, shortage of trained pharmacy personnel and lack of system for drug regulation and quality 
assurance. Faith-based health care providers involved in pharmaceutical supply chain do exist extensively as 
drug supply organizations or as a Christian Health Association with a pharmaceutical supply chain. They have 
been in existence in Africa for a very long time now contributing to the national pharmaceutical system in 
Africa. The review revealed that faith-based involvement in pharmaceutical chains tended to improve access 
to the general population and inserted additional pharmaceutical supplies into the national pharmaceutical 
system – which tended to strengthen the broader public private partnership between faith-based health 
providers and the public sector. This analysis confirmed that African pharmaceutical supply systems continue 
to face challenges. There is a major evidence gap relating to PNFP contribution to pharmaceutical systems – 
as is evidenced by this study on faith-based contributions to African pharmaceutical systems (which can be 
understood as a tracer for a broader concern). There is a particular lack of evidence about the national supply 
chain, and how faith-based PNFP engagement contribute or detract from the national pharmaceutical supply 
chain. FB-DSOs complement the public pharmaceutical system by improving access to medicines and related 
commodities in Africa.  
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Glossary of key terms 
This glossary clarifies key terms. 
Christian Health 
Association 
These are national networks of faith-based health providers that are common 
in Africa. Pharmaceutical supply is part of the services that are provided by CHA 
Faith-based drug 
supply 
organization 
These are faith-based organizations involved in the pharmaceutical supply 
Faith-based 
organizations 
These are organizations whose values are based on a faith. For this review the 
faith-based organizations are those of the Christian faith 
Pharmaceutical 
supply chain/ drug 
supply chain 
This the process through which drugs and medical supplies travel from the 
manufacturer to the wholesalers who then distributes to the central or regional 
medical stores, retail pharmacy outlet, hospitals, clinics, dispensaries to the 
patients. 
Pharmaceutical 
systems  
The pharmaceutical system comprises of the actors in the pharmaceutical 
sectors and how they interact with the other building blocks health systems to 
ensure access to quality affordable medicines (Hafner et al 2016) 
Source; Author, (drawing on and adapting commonly held definitions) 
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PART A PROTOCOL 
The nature and extent of faith-based involvement in African pharmaceutical systems 
Introduction 
The pharmaceutical sector is central to the building blocks of every health system (World Health Organization 
2007). The value of a dedicated drug supply chain cannot be underestimated in achieving a sound and effective 
health care outcome. A health system is defined as the combination of all organizations, people and actions 
with primary intent to promote, restore or maintain health (World Health Organization 2007). A strong 
relationship between the pharmaceutical sector, medicines and technology and the other building blocks are 
of utmost importance in realizing improved health outcomes, quality care and financial protection (World 
Health Organization 2007). However, existing evidence from Low and middle-income countries (LMICs) 
indicates that little attention is paid to strengthening this relationship, resulting in a large proportion of LMIC 
populations being unable to access much-needed pharmaceutical medical supplies (Bigdeli et al. 2012; 
Cameron et al. 2009). The World Health Organization (WHO) states that key components of “well-functioning 
health system emphasizes universal equitable access to essential medical products, vaccines and technologies 
of assured quality, safety, efficacy and cost-effectiveness, and their scientifically sound and cost-effective use” 
(World Health Organization 2007). Evidence has also shown that user fee exemptions, including no fee on 
prescribed medication for elderly patient on chronic medication treatment has promoted access greatly, and 
can enhance health outcomes and strengthen the health system as a whole (Mwita et al. 2017; Prinja et al. 
2015).  
The ‘pharmaceutical sector’ as part of the health system is broad – and similarly to other health sectors can 
be divided into public and private sectors. The private pharmaceutical sector includes those pharmaceutical 
organizations that are not run by the government, including private for-profit (PFP) and private not-for-profit 
(PNFP) organizations (Patouillard et al. 2007). PFP organizations includes wholesale and retail pharmacies and 
drug stores, and drug manufacturing companies. The PNFP organizations include local and international non-
governmental organizations (NGOs) and faith-based health care providers1 (FBHPs) (McCabe 2009; Trouiller 
et al. 2002). A strong public health sector is likely to offer a better pharmaceutical supply services to LMIC 
patients and to improve their experience when seeking health care (Bigdeli et al. 2012; World Health 
Organization 2007). However, the public health sector in most LMIC settings is generally challenged and 
influenced by circumstances that make the pharmaceutical stock levels in the health facilities of LMICs 
unreliable with resultant irregularities of pharmaceutical supplies in health facilities (Cameron et al. 2009). 
                                                          
1 Faith-based health care providers- refers to all the different health care services provided by faith-based organizations 
while FB-SOs is only for those involved in the pharmaceutical supply chain 
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These circumstances include poor financing, lack of infrastructure and resource availability, as well as several 
factors linked to the relationship between the public health sector and the private pharmaceutical sector 
(Bigdeli et al. 2012; Cameron et al. 2009; Chuma et al. 2010; Wales et al. 2014). Existing evidence from LMICs 
has shown that patients are compelled to buy pharmaceutical supplies from the private pharmaceutical sector, 
usually at a higher cost that is not affordable to many patients (World Health Organization 2004). Moreover, 
others resort to private pharmacies and chemist either because they cannot afford to pay, or they want to 
avoid paying user fees (Berman et al. 1995a). Several studies indicated that out of pocket payment for 
pharmaceutical supplies account for over 50% of the total expenditure on health in LMICs (Bennett et al. 1997; 
Berman et al. 1995b; Bigdeli et al. 2015).  
Unfortunately, few efforts are made to resolve this issue in LMICs and the lack of medicines and 
pharmaceutical supplies in public health facilities is increasingly accepted as a norm, negatively influencing 
health seeking behaviors and equity for its population (Goudge et al. 2009; Wales et al. 2014; Workneh et al. 
2016). In LMICs, 66% of prescribed medicines can be found in private facilities as compared to 35% in the 
public sector - although medicines from the private sector are often costly and unaffordable by the poor 
(Bloom et al. 2014; Cameron et al. 2009). International efforts have played a role in the mobilization of much-
needed funds for health systems strengthening, in which drug supply chain strengthening is a part (Clinton & 
Sridhar 2017). Broader public sector literature also provides evidence that most LMICs do not have 
pharmaceutical manufacturing companies, and the state usually procures medicines from private 
international pharmaceutical companies (McCabe 2009). Yet, little or no support is in place to empower the 
few countries with local pharmaceutical manufacturing companies, including pharmaceutical supply 
wholesalers - which is one step forward in ensuring such an industry thrive and expand with a ripple effect to 
those countries without (McCabe 2009).  
In Africa and LMICs in general, developing the capacity of the governments to regulate the pharmaceutical 
sector and market is crucial (Bate et al. 2008; Bloom et al. 2014; McCabe et al. 2011). Government regulation 
differs from country to country and this hinders building trusting relations with regards to the quality and flow 
of medicines in the market (McCabe 2009). Evidence from multiple studies shows that monitoring and 
regulatory control of the pharmaceutical sector in LMICs is weak across all parts of the pharmaceutical supply 
chain including delayed selection of essential medicines; calculations of quantities to purchase; ability of 
hospitals and pharmacies to purchase medicines; and warehousing and distribution of medical products 
(Berman & Hanson 1993; Bigdeli et al. 2012; Brugha & Zwi 1998; Gilson et al. 1994; McCabe 2009). This 
weakness in regulatory control could be one of the reasons for the difficulty in monitoring the private sector 
with regards to how resources received from government are been used (Gilson et al. 1994), and also the high 
flow of medicines in the informal sector (Bloom et al. 2011). 
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The private sector has led efforts to improve pharmaceutical systems in developing countries with programs 
in supply chain management and medicines quality assurance systems strengthening (Bennett et al. 1997). 
These efforts have encompassed the development of innovative approaches and tools and addressed disease 
programs and cross-cutting issues such as medicines safety, pharmacovigilance and post market surveillance 
(Mounier-Jack et al. 2010; Warren et al. 2013; Windisch et al. 2011). One crucial priority is to strengthen the 
pharmaceutical supply chain to ensure the supply of quality-assured medicines and related commodities 
(Hamilton et al. 2016). This is a serious challenge for LMICs and ineffective and flawed practices are common 
with private pharmacies assuming roles to treat common and childhood diseases (Berman et al. 1995a; 
Berman et al. 1995b) which, although flawed, may be the only access for ill members of the community having 
to cover long distances to get to health facilities and clinics. The private sector in the form of PNFP 
pharmaceutical sector actors can increase and enhance services for the poor and vulnerable communities in 
rural and hard to reach areas (Berman et al. 1995a; Gilson et al. 1994). The   pharmaceuticals supplied to 
patients by the PNFP organizations are in most cases cheaper than at PFP because NGOs and mission 
organizations purchase medicines at subsidized rates from government central medical stores or through 
donations (Gilson et al. 1994).  
A strong pharmaceutical system has established leadership and governance; effective regulation, robust 
financing for products and their management; a well-trained workforce and a well-run organization (from 
national institutions to local drug shops); reliable product and patient information; medical products and 
technologies available when and where needed; and services that promote rational use and protect safety 
(Bigdeli et al. 2012; Bigdeli et al. 2014; World Health Organization 2007). 
It is evident from the literature that in LMICs, partnership between the public and private pharmaceutical 
sector have helped positively in health systems strengthening through improved access to medicines and 
related commodities (Bennett et al. 1997; Chirwa et al. 2013). For example, the Medicine Transparency 
Alliance (MeTA) initiative in developing countries supported a mix of government and private stakeholders to 
aid access to affordable quality essential medicines (McCabe 2009). The government can partner with the 
private sector by creating the enabling environment for them through tax exemption on medicines for services 
offered by NGOs and FBHPs (Gilson et al. 1994), promoting the sale of generic medicines in private sector, and 
duty-free entry on pharmaceutical raw materials for essential medicines (Bennett et al. 1997). For example, 
in Malawi, the Christian Health Association Malawi (CHAM) procures pharmaceuticals from the central medical 
store at cheaper subsidized prices, and the Christian Health Association Ghana (CHAG) are exempted by the 
government from paying import duties on medicines and medical supplies (Gilson et al. 1994). This will 
translate into having a committed private sector and increased access to medicines and hence improved 
health outcomes (Gilson et al. 1994). In addition, working as a team and collaborating with other stakeholders 
both locally and internationally is of utmost importance in achieving the desired health outcomes (Bennett et 
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al. 1997). For example, in South Africa the Antiretroviral therapy (ART) programmes emerged through 
collaboration and support by government, NGOs, schools and local business (De Waal & Nakedi 2005). 
Partnership between the government and FB-DSOs are seen to be of utmost importance as they provide 
services to poor and vulnerable (Banda et al. 2006), therefore can fill in the gap due to inefficiencies of the 
government (Green 2008).   
Faith-based health providers (FBHPs) are PNFP organizations associated with or inspired by religion or religious 
beliefs (Chatters et al. 1998; DeHaven et al. 2004). They play an important role in the medicine supply chain 
in many LMICs (Banda et al. 2006; Olivier et al. 2015). The services provided by FBHPs are usually done in 
agreement with the government (World Health Organization 2008) and complement government services, 
often the only service available in rural and remote areas where government services are less accessible 
(Banda et al. 2006; Berman et al. 1995b). Governments often rely on FBHPs as a partner in service provision 
for a wider coverage of the population in need, through alignment of priorities, contracts and service-level 
agreements (Whyle & Olivier 2017). However, the contributions of FBHPs in pharmaceutical supplies chains 
are largely unknown, and these services are often rendered outside of the mainstream of the national 
government (Banda et al. 2006; World Health Organization 2008). Several studies have suggested that 
communities trust FBHPs to provide medicines and services of good quality (Asenso-Okyere 1995; Banda et 
al. 2006; Gilson et al. 1995; Kelly et al. 2010; Shojo et al. 2012). Their close links to communities and influence 
over them provide FBHPs with an ideal opportunity to promote confidence and address cultural factors 
contributing to morbidity and mortality (Chatters et al. 1998). The financial resourcing of FBHPs is diverse and 
could take the form of financial support from central government and or drug donations (Ascroft et al. 2011). 
In Malawi, for example, FBHPs are affiliated with government (Dowling 2011) and provide services inclusive 
of free medicines supply to the poor and hard to reach areas (Chirwa et al. 2013), subsidized by government.  
When compared to the public sector, it is argued that FBHPs have been as (if not more) effective in outreach, 
nourishing community trust and participation, and providing cost effective and quality care for the 
marginalized and poor (Berman et al. 1995a; Kelly et al. 2010; Rookes 2010). However, the above perceived 
qualities are over-shadowed by perceived characteristic weaknesses such as lack of human resource, doubtful 
financial sustainability, poor record keeping and preferential service (Banda et al. 2006; Gilson et al. 1995; 
Grimaud 1998). Other reported weaknesses were in the deficiency of system management and control of 
medicine supply chains (Banda et al. 2006), with some FBHPs lacking adherence to rational drug use, as having 
poor storage facilities, as well as nonadherence to supply and distribution systems and policies on drug 
donation (Banda et al. 2006). Even in instances where medicines are supplied for free, the consultation or 
hospital admission fees often charged by FBHPs can act as a barrier to access the service. For example, as 
reflected in a Zambian case where patient turnout at FBHPs for TB services was low, despite free anti-
tuberculosis medicines, as patients had to pay fees for consultations (Berman et al. 1995b). CHAM was 
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contracted by government to provide services to the poor at no fee - but this was challenged by unreliable 
and irregular supply of medicines at the central medical stores. As a last resort they procured medicines from 
private pharmaceutical companies as a result patient had to pay for medicines and related commodities 
(Chirwa et al. 2013). This resulted in strained relations between government and CHAM, which negatively 
influenced drug availability in the facilities, with worsened health indices (Chirwa et al. 2013). 
FBHPs also play an important role in strengthening national LMIC health systems – and therefore possibly also 
in strengthening their national pharmaceutical systems (Berman et al. 1995a; Gilson et al. 1994; Olivier et al. 
2012a; Olivier & Wodon 2012b; Olivier et al. 2012b). However, evidence of the contribution by FBHPs is 
fragmented (Olivier et al. 2015). There is little information on FBHPs as non-profit providers in the health 
sector, and almost nothing relating to pharmaceutical systems or even just a basic assessment of drug supply 
(McCabe 2009; Olivier et al. 2015). To fully understand the role of FB-DSOs in pharmaceutical systems in Africa 
and respond to these knowledge gaps, we need to be able map and understand FB-DSO pharmaceutical 
systems (the presence of services, and supply chain contribution). 
Research question 
What private-not-for-profit faith-based pharmaceutical supply chains exist in Africa; do they have shared 
characteristics; and what is their function within their national pharmaceutical systems? 
Objectives  
• To map and explore the nature and extent of FB-DSOs supply chains in Africa  
• To reflect on any characteristics or challenges shared by FB-DSOs pharmaceutical providers/systems 
• To understand how FB-DSOs’ fit within national pharmaceutical systems 
Rationale for the study 
We will examine the health activities of FBHPs specifically related to pharmaceutical supply chain involvement. 
Also, we will examine the published literature on FB-DSOs services as related to pharmaceutical supply chain 
management, to ascertain the nature and function of these activities. The study is not intended as an 
exhaustive review of health service activities in FB-DSOs; but rather, as a very initial exploratory step to 
highlight faith-based pharmaceutical supply chains that exist in Africa.  
To the best of our knowledge, this is the first review of its kind to look at the nature and function of FBHPs in 
the pharmaceutical supply chain of Africa. We therefore aim to initiate the closing of a significant knowledge 
gap. The review should also identify opportunities for further research and inform policy formulation on 
pharmaceutical supply in Africa – as well as public private partnership. 
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Methodology 
This is a systematic review study. Systematic review is useful in identifying and analyzing existing evidence to 
gain a better understanding and make connections between similar topics (Cooper 2010; Cooper 2015). This 
systematic review study will consist of two parts. The first part will consist of a scoping review, which will 
inform the qualitative systematic review that follows – and will provide a better understanding of 
pharmaceutical systems and private providers in LMICs (see Part B). The second part, a qualitative Systematic 
review, will focus on a more narrowly defined research question (as defined in Part B), focused on faith-based 
involvement in the pharmaceutical supply chain in Africa (Part C). A systematic review is a research method 
that pulls together the research of other people on a particular topic over a period of time with the aim of 
giving a comprehensive picture of that topic through assessment of the studies (Campbell Collaboration 2014; 
Hannes et al. 2007). The systematic review will be shaped by themes developed in the scoping review. 
This review study is framed as a Health Policy and Systems Research (HPSR) project, seeking to map out the 
involvement of FBHPs in pharmaceutical supply chains and its role in health systems strengthening in Africa. 
HPSR is multi-disciplinary in nature and commonly integrates data/information from different sources, as is 
necessary in this exploratory study (Gilson 2012). 
Phase 1: Scoping review  
The scoping review will help in mapping out available literature which will be used to develop a more focused 
search strategy over a specified period (Roehrich et al. 2014). This will provide a clear concept of the topic by 
being able to synthesis and analyze the available information including published, unpublished and non-
researched material (Davis et al. 2009). Scoping review methods are suitable for studies comprising of work 
done in LMICs and are used in HPSR to systematically synthesize data and advice policy makers, health workers 
and researchers in decision making based on evidence for the health system (Tricco et al. 2017). 
From the scoping review key words and search terms will be developed from the available literature that will 
be used for conducting the systematic review study (Hammerstrøm et al. 2010; Tranfield et al. 2003). As part 
of the scoping review, key word searches in PubMed, Medline, EBSCOhost, Scopus, Web of science and grey 
literature from Google and Google Scholar search will be done. We anticipate that search terms for this phase 
will include ‘cold chain’, ‘drug distribution’, ‘supply chain’, ‘drug supply’, ‘ART’, ‘Medicine’, ‘Medicine price’, 
‘procurement’, ‘dispensary’, ‘health’, ‘hospital’, ‘clinic’, ‘health system’, ‘health care system’, ‘health service’, 
‘policy’, ‘NSP’, ‘non-profit’, ‘not-for-profit’, ‘PPP’, ‘private’, ‘public’, ‘faith-based’ and ‘mission’. The scoping 
review search will not be restricted to a specific period. Relevant citations from selected articles will be 
searched and included in the study. The search in this phase will focus on documents and information relating 
to all LMICs - and this search will be limited to literature in English. Both grey literature and published literature 
will be included in the scoping review phase. 
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Phase 2: systematic review 
This phase of work will be the qualitative systematic review of the faith-based involvement in pharmaceutical 
supply chains in Africa. This method is appropriate for studies looking to put together available literature for 
the purpose of evidence-based policy and decision-making (Mulrow 1994). This review needs to include a 
rigorous, unbiased and objective search that is reproducible (Lefebvre et al. 2008). A range of databases will 
be utilized to improve the value and effectiveness of this work (Akobeng 2005), including: PubMed, Africa 
Wide, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science and Google Scholar. 
These databases were selected based on their appropriateness for the research topic and to ensure that the 
full range of available evidence is included (Cronin et al. 2008). Google will also be searched to capture further 
grey literature.  
Search terms for the systematic review phase will be guided by key words identified in the scoping review 
phase. The identification of these search terms will be done carefully to ensure that relevant information to 
answer the research question will be identified (Cronin et al. 2008). As such standardized subject terms, 
synonyms and related terms will be included and accounted for to ensure that relevant documents are 
identified (Lefebvre et al. 2013). A Health Sciences Faculty Librarian will be consulted for input and assistance 
to clarify and finalize the search terms (Bown & Sutton 2010; Lefebvre et al. 2008). This review will use three 
sets of search terms – pharmaceutical, non-state provider and region – and each of these sets will include 
standardized subject terms, synonyms and variations, as recommended by Lefebvre et al (2008). The terms 
will be joined by the Boolean operators ‘OR’ and ‘AND’ (Lefebvre et al. 2008). Terms within each of the three 
sets will be joined by ‘OR’ and then these sets will be joined by ‘AND’. The review will include literature written 
in English and will not be limited to any specific time frame. The reference list of the studies identified will be 
searched for additional relevant studies (Hammerstrøm et al. 2010). The records of all search terms, databases 
and results will be kept (Lefebvre et al. 2008). The search strategies used for each database will be included in 
the Appendix. Duplicates will be removed from the results of the database searches and the remaining 
documents will be screened based on title and abstracts to retrieve the relevant documents to be included for 
full detail reading and analysis. 
This qualitative systematic review will seek to include all types of data, qualitative and quantitative – as a 
synthesis approach is necessary given the exploratory research question (Dixon-Woods et al. 2006). This study 
will take cognizant of the challenges associated with the synthesis and review of qualitative data to ensure 
rigor (Dixon-Woods et al. 2006). 
Data extraction 
Following the systematic review process, documents that meet the selection criteria will be analyzed. The 
initial scoping review will identify themes that will be taken into the systematic review (and provide further 
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clarity on what data would be most relevant for the research question). This is a useful approach as deciding 
on appropriate extraction approaches can be a challenge in systematic reviews (Thomas & Harden 2008). A 
data extraction table will be applied to minimize bias and increase rigor, by ensuring the review process is 
standardized throughout. The data extraction table will be used as a guide for the analysis process and 
facilitate data management which can be used by future researchers (see Appendix A). 
Data analysis 
Thematic analysis and synthesis will be applied across the whole review study. In the systematic review part 
(as is standard in qualitative systematic review), the analysis of the data begins after the systematic search is 
completed. All the articles that met the selection criteria will be analyzed in the same way so that enough 
information will be gathered to be able to answer the research question as accurately and completely as 
possible. The quality and heterogeneous nature of the data determines the method to use in the analysis and 
synthesis of the data (Strong et al. 1997). Data synthesis applied to the stage at which the data is extracted 
from all the documents included in the review is combined (Mays et al. 2005). Narrative synthesis is an 
approach used in systematic review studies to synthesize evidence from multiple sources (Mays et al. 2005). 
Narrative synthesis method allows researchers to summarize and interpret evidence from published and other 
sources of information and is a method widely used in systematic reviews (Mays et al. 2005). 
Thematic analysis is “a method for systematically identifying, organizing and offering insight into patterns of 
meaning (themes) across a data set” (Clarke & Braun 2014). It is a data analysis method widely used in 
qualitative research. Thematic analysis is commonly used in narrative approaches to data synthesis (Mays et 
al. 2005). Thematic analysis is also one of the methods to use when doing a research in an area that is under-
researched (Braun & Clarke 2006). Patterns are identified by the analyst during the process of data 
familiarization and data extractions which are then developed into themes (Braun & Clarke 2006). According 
to Braun & Clarke (2006) there are six steps in doing thematic analysis: Step one consists of data familiarization 
through reading and re-reading of the documents to become aware of the content information. Step two 
consists of code production from the data through the familiarization. The codes are reflective of the features 
of the documents reviewed in terms of relevance and interest to the analyst. The entire dataset must be coded 
because this needs to come together at the end for the analysis (Braun & Clarke 2006). Step three is that of 
searching for themes through codes examination. The codes are sorted into themes ensuring that all the 
relevant codes are within an identified theme (Braun & Clarke 2006). Step four consists of refining themes, 
this is wherein the initial themes are checked against the entire dataset to ensure that they are reflective of 
the data and that the research question has been answered (Braun & Clarke 2006).  Step five is the defining 
and naming the themes. Step six is the write up. This is the stage wherein the researcher analytically narrates 
the story the data told in the context of the existing literature (Braun & Clarke 2006). Thematic analysis will be 
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applied at several stages of this study – including the scoping review and in the final synthesis phase of the 
systematic review. 
Rigor  
Rigor must be maintained throughout the research process to ensure reliability and add credibility to the 
findings. According to Mays et al (2005), to ensure rigor in a systematic review the following mechanisms must 
be included: clearly describing the aim of the review, careful description of the methods in detail such that 
another researcher could repeat the review using the same methods, choice of method made must be 
justifiable, and, the sources of evidence used in the review are appropriate to the research question. As stated 
earlier, to ensure rigor of the study multiple databases (EBSCOhost, PubMed, Web of Science, Google Scholar 
and google) will be searched with search terms and table checking by supervisors and a librarian at health 
sciences library. The inclusion of grey literature and multiple database searches will guard against publication 
bias and is necessary given the general paucity of information on FBHPs’ involvement in pharmaceutical 
systems. 
Risks and benefits  
As a systematic review this study has little or no risk. This study should be beneficial for researchers, policy 
makers and health system actors – including public sector and PNFP/FBHP stakeholders. 
Study limitations 
This systematic review study is most significantly limited by the (anticipated) absence of robust evidence and 
published literature relevant to FBHP pharmaceutical supply chains. Even though this study is intended and 
designed to be an initial exploratory study (adequate for mini-thesis purposes), the fact that this is a sector 
that has remained largely ‘invisible’ for decades (Banda et al. 2006), means that we anticipate that the 
evidence will also be limited and limiting. In addition, as is standard in such review approaches, the 
researcher’s understanding, and perspective might influence the assessment and judgement of suitability of 
the selected studies which can lead to bias. This will be managed through the application of a critical appraisal 
tool and checklist (Mays et al. 2010), and selections will be double-checked by study supervisors. This review 
is also limited by the fact that it only includes English-language publications, which might result in exclusion of 
relevant documents published in other languages (although this is less likely, given the general paucity of 
literature on this topic generally). This review is also limited by the scoping review being conducted by the 
researcher only. The LMIC and Africa focus of the later systematic review also creates limitations – although a 
broader scope would also be limiting, since this limitation at least allows for comparison across similar health 
system contexts. The literature search is limited to databases that are accessible through the University of 
Cape Town (UCT), although the researcher will make significant efforts to access any further materials by direct 
communication with authors or requesting materials from publishers. 
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Ethics 
This study will be using a systematic review methodology and as such a formal ethical approval from an ethical 
review board is not required. All documents that will be used in this study are publicly accessible. 
 Dissemination of findings 
The full thesis will be publicly available through the University of Cape Town open access platform. Part C of 
this thesis will be submitted for publication in an academic journal. Summaries of relevant results will be 
shared with key health system actors in Africa (public and FBHP). 
 
Timeline  
Table 7: Timeline of systematic review study 
Component   Activity Timeline 
Part A protocol  Subject formulation  November 2017 to February 2018 
Draft  February 2018 
Edits  April 2018 
Part B scoping review  Research  November 2017- March 2018 
Draft  May 2018  
Edits  September 2018 
Part C Systematic review Draft  October 2018 
Edits  November 2018 
Intention to submit December 2018 
Submission  February 2019 
Source; Author 
 
Budget  
This study is funded through bursaries from the Health Policy and Systems Division (HPSD) and the Faculty 
International Student Bursary (FISB) fund at UCT. 
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PART B: Scoping review 
The organization of pharmaceutical systems in low and middle-income 
countries: a scoping review 
Introduction  
According to the World Health Organization (WHO), a well-functioning health system ensures that the 
population have equitable access to quality medicines and related commodities at affordable cost 
(World Health Organization 2007) – and a well-functioning pharmaceutical system the same: 
A pharmaceutical system consists of all structures, people, resources, processes, and their 
interactions within the broader health system that aim to ensure equitable and timely access 
to safe, effective, quality pharmaceutical products and related services that promote their 
appropriate and cost-effective use to improve health outcomes (Hafner et al. 2016, p.572).  
Pharmaceutical systems are considered to be a ‘subsystem’ of their health systems - playing a key role 
in health system functioning (Hafner et al. 2016). Medical products, vaccines and technologies is 
considered as one of the key building blocks of the health system as it play an important role in 
achieving improved health outcomes and health systems strengthening (World Health Organization 
2007). The relationship between medical products, vaccines and technology and the rest of the 
building blocks of the health systems is very important in achieving the desired health outcomes and 
financial protections for the health service users (De Savigny & Adam 2009; World Health Organization 
2007).  
Like health systems, pharmaceutical systems are made up of a mix of public and private actors and 
entities. Private entities (actors and institutions) that are not run/owned by the government 
(Patouillard et al. 2007) - and inclusive of private-for-profit (PFP: such as pharmaceutical importers, 
manufacturers, wholesalers and retail outlets), and private-not-for-profit (PNFP, such as: local and 
international non-governmental organizations, faith-based health providers1 (FBHPs) and charity 
organizations) (McCabe 2009; Trouiller et al. 2002). However, no pharmaceutical system can be purely 
‘public’ as all pharmaceutical supply chains include some private input or involvement – such as 
pharmaceutical companies producing medicines, or logistics companies transporting medicines 
(Bennett et al. 1997; Mackintosh et al. 2011; McCabe 2009). 
                                                          
1 Faith-based health care providers- refers to all the different health care services provided by faith-based 
organizations while FB-SOs is only for those involved in the pharmaceutical supply chain 
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In many low- and middle-income countries (LMICs), patients mostly pay for medicines, even when 
other services such as consultations, are free of charge (McKee et al. 2006). This is because health 
facilities ultimately procure medicines from the private sector (Bennett et al. 1997; McKee et al. 2006) 
– even if it is the government procuring from the private sector through central medical stores. And 
also due to frequent (normalized) stock outs in the public sector (Harding et al. 2013). In many LMICs, 
the private pharmaceutical sector continues to serve as the main source of care for the poor and 
vulnerable groups (Berman et al. 1995a; Patouillard et al. 2007; Smith 2009), and in many contexts, 
services are provided by local pharmacies, wherein patients must pay a fee (Smith 2009). In addition, 
studies have shown that some patients prefer and utilize the private pharmaceutical sector over the 
public pharmaceutical sector (Chalker et al. 2005; Chuma et al. 2007; Khuluza & Heide 2017; Mills et 
al. 2002).  For example, patients preferred private pharmacies and dispensaries over those of the 
government because of the reported poor attitudes of the service providers and lack of trust in the 
public sector in handling patients (Chuma et al. 2007). 
It has been noted that the private health sector is often more efficient than the public sector in most 
LMICs – both PFP and PNFPs (Chalker et al 2005; Khuluza Khuluza & Heide 2017). One explanation, for 
PNFPs, is that the PNFP sector receives support from different organizations both locally and 
internationally (Olivier et al. 2015). It is in this light that many LMIC governments are recognizing the 
role of the private sector through public private partnerships (PPP) to improve the drug supply chain, 
strengthen the pharmaceutical sub-system, and thereby strengthen national health systems more 
broadly (Bennett et al. 2005; Bennett et al. 1997; Chirwa et al. 2013). 
Scoping review method 
A scoping review was conducted to review the evidence on faith-based PNFP pharmaceutical supply 
chains in LMICs. The review seeks to examine and highlight the available literature on the different 
types of pharmaceutical sectors and suppliers, challenges and possible interventions in LMICs more 
broadly – and then consider the role of FBHPs in these pharmaceutical systems in LMICs. 
The review was conducted from November 2017 to March 2018. The literature search included 
academic articles and grey literature using PubMed, Medline, EBSCOhost, Scopus, Google and Google 
Scholar search. Search terms used included ‘cold chain’, ‘drug distribution’, ‘supply chain’, ‘drug 
supply’, ‘ART’, ‘Medicine’, ‘procurement’, ‘dispensary’, ‘health’, ‘hospital’, ‘clinic’, ‘health system’, 
‘health care system’, ‘health service’, ‘policy’, ‘NSP’, ‘non-profit’, ‘not-for-profit’, ‘PPP’, ‘private’, 
‘public’, ‘faith-based’ and ‘mission’ ‘Africa’, ‘Low and Middle-income countries’, ‘LMIC’, ‘sub Saharan 
Africa’ (and the associated countries).  
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The search was limited to publications in English and did not apply any publication year limitations – 
in order to capture as much relevant information as possible. Reference lists of included articles were 
searched, and relevant documents were identified and included in the review. In addition, documents 
from institutional websites including the WHO, the World Bank, and known FBHP pharmaceutical 
institutions were also searched and relevant documents included in this study. 
Types of important actors in LMIC pharmaceutical sector 
The WHO defines the pharmaceutical sector as  
…the various actors (e.g., government, private for-profit organizations, private not-for-profit 
organizations) engaged in the ‘medicine chain’, which includes research and development; 
clinical trials; filing patents; manufacturing; registration; selection, procurement and 
distribution of essential medicines; inspection of manufacturers and distributors; prescribing; 
dispensing; pharmacovigilance; and the control of promotion (World Health Organization 
2009). 
This definition is a little different to the understanding of a pharmaceutical system (above) and focuses 
on the practices of actors within the sector. LMIC pharmaceutical sectors generally include the 
public/government pharmaceutical sector, PFP and PNFP institutions, see diagram below (Hafner et 
al. 2016; Kohler et al. 2014; Patouillard et al. 2007; Trouiller et al. 2002; World Health Organization 
2009).  
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Figure 1: Pharmaceutical Sectors in LMICs (Source; Author) 
Procurement in public LMIC pharmaceutical sectors 
The public pharmaceutical sector is funded by revenue from tax and sometimes receives support from 
international organizations through donor funding (Cameron et al. 2009; Cameron et al. 2011; 
Trouiller et al. 2002). In some LMICs, for example Ghana, most medicines are manufactured locally 
(Asamoah et al. 2012) and then distributed to regional health facilities. For others, medicines are 
procured by the government from private companies within or outside the country and then supplied 
to the regional health facilities (Cameron et al. 2009; McCabe 2009). 
Procurement in private for profit (PFP) pharmaceutical sector   
PFP pharmaceutical companies are drug supply sector mainly focused on making profit these can be 
subdivided into wholesale and retail2 (Vogel & Stephens 1989). The wholesale sector supply medicines 
to the public as well as private sector. For example, countries that do not manufacture medicines 
locally, procure medicines from these companies (Barnes et al. 2008; McCabe 2009). Also, wholesale 
companies supply medicines to private pharmacies and drug stores. In most African countries, most 
of the people receiving medicines from pharmacies pay out-of-pocket (Patouillard et al. 2007).  
                                                          
2 Retail pharmaceutical sector comprise of pharmacies, drug stores and chemical sellers 
Pharmaceutical 
Sector
Public 
Central Medical 
Stores
District Medical 
Stores
Hospital 
Pharmacies
Dispensaries in  
clinics
Private
Private For 
Profit
Manufacturers Import
Whole sale Retail
Private Not for 
Profit
Non 
Governmental 
Organisation
Faith-Based
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Private-not-for-profit (PNFP) pharmaceutical sector 
The services of FBHPs working in the pharmaceutical sector account for about 40% coverage in sub 
Saharan Africa (Banda et al. 2006). In some African countries, FBHPs are the only health services 
available in rural and remote areas (Green 2008). For example, FBHPs in Malawi are affiliated with 
government (Dowling 2011) and provide services inclusive of free drug supply to poor and hard to 
reach areas (Chirwa et al. 2013).  
Some PNFPs receive medicines from international donors or purchase medicines from the local 
manufacturing companies or the central medical stores (Dowling 2011). These donors3 sometimes 
procure medicines from foreign pharmaceutical companies which delivers these medicines to the 
central medical stores of the recipient country, FBHPs facilities and other health centres (McCabe 
2009). 
Public private partnership in the pharmaceutical sector 
In some LMICs the government has worked closely with the private pharmaceutical sector (PFP and 
PNFP) in improving access to medicines and related commodities (Bennett et al. 1997). It is evident 
from the literature that the collaboration between the public and non-governmental organizations 
(NGOs) has yield success in several countries (Berman et al. 1995a; Gilson et al. 1994; Zafar Ullah et 
al. 2006). In Bangladesh for example, the government worked in collaboration with an NGO in the 
treatment of tuberculosis (TB), and this improved the access to TB medicines and compliance (Zafar 
Ullah et al. 2006). 
The Christian Health Associations (CHA)4 have worked closely with the public sector in improving the 
pharmaceutical supply chain in many developing countries. Several studies have shown that most of 
these associations procure medicines from the ministry of health and private suppliers (Ballou-Aares 
et al. 2008; Grimaud 1998) or through the central medical stores at subsidized rates for these 
organizations to be able to provide medicines and other services to the population in need (Ballou-
Aares et al. 2008; Gilson et al. 1994). For this partnership to be successful and yield the desired 
outcome, (Bennett et al. 1994) it is suggested that public health system must strengthen its regulatory 
systems to ensure that populations benefit from the resources that these providers receive from the 
government (McPake & Hanson 2016). 
PPP also helps to strengthen the PNFP pharmaceutical sector, as evidence from several studies have 
shown that most PNFP pharmaceutical sector buy medicines at a subsidized rate, some benefit from 
                                                          
3 Example of donor organizations- Catholic Relief Services (CRS), PEPFAR, AIDS Relief, MeTA, Global fund 
4 Christian Health Association are national networks of faith-based health providers that are common in Africa 
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tax wavers on importation of medicines and other pharmaceuticals (Gilson et al. 1994; McPake & 
Hanson 2016) and others receive medicines and other support from the ministry of health to provide 
services to poor and vulnerable (Chirwa et al. 2013). 
Types of pharmaceutical supply chains in LMIC 
There are many types of pharmaceutical supply chains in LMICs. These include the central medical 
stores, autonomous suppliers, direct delivery system, primary distributors and private suppliers. The 
main aim of the pharmaceutical system is to provide access to quality and affordable medicines (World 
Health Organization 2007; World Health Organization 2009). The following paragraphs will look at 
these supply chains individually. 
 Central Medical Stores (CMS) 
The CMS can supply medicines and other pharmaceuticals that are procured by the government or 
from international donors to the regional or provincial districts, public hospitals and other health 
facilities. The medicines quality is being monitored by both the central medical stores and regulatory 
authorities (World Health Organization 2012). The CMS is financed through budget allocation and or 
donor funding (McCabe 2009; McCabe et al. 2011; World Health Organization 2012).  
The CMS also serves as a storage warehouse in many LMICs, to store medicines before being 
distributed to other regions or districts (Yadav 2011; Yadav 2015). This is very helpful as most regional, 
and district medical stores do not have the correct infrastructure for the storage of medicines and 
other medical supplies (Yadav 2011). For example, the national medical stores in Uganda, oversees 
procurement, storage and delivery of   pharmaceuticals to the national, regional and district referral 
hospitals, health and sub-health centers and the parish health centers (Trap et al. 2016). 
 Autonomous supply agency  
In some LMICs, an independent supplier oversees procurement, storage and distribution of 
pharmaceuticals (Dickens 2011). The quality of medicines is being monitored by the drug regulatory 
authority and procurement team (World Health Organization 2012). This is an alternative to CMS 
wherein the management of the CMS is changed but they will still be working in the existing CMS 
structure (Ali & Omer 2011). In some LMICs, this system is also referred to as semi-autonomous central 
medical stores. 
 Direct delivery system 
In this system, the supplier delivers the pharmaceutical products to the regional, districts and major 
health facilities after being contacted by the procurement team. The quality of the medicines is 
monitored by the procurement team and drug regulatory authorities (World Health Organization 
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2012). For example, in some LMICs, the regional and district medical stores receive   pharmaceuticals 
directly from the private suppliers and they in turn distribute these commodities to the hospital and 
other health facilities (McCabe 2009; McCabe et al. 2011; Yadav 2011). 
Primary distributor system 
The pharmaceutical procurement team of the national government contract a primary distributor that 
is responsible for the storage and distribution of medicines and other pharmaceuticals procured from 
different pharmaceutical suppliers. The quality assurance of medicines is done by the drug regulatory 
authority (World Health Organization 2012). In this case the medicines and related commodities do 
not go through the CMS. For example, in Tanzania the Mission for Essential Medical Supplies (MEMS) 
receives medicines from different suppliers and distribute them to the health facilities in the country 
especially those in rural areas (White et al. 2013).  
Private supply 
The procurement and distribution of pharmaceuticals is managed by the private supplier. The quality 
assurance is done by the national regulatory authorities (World Health Organization 2012). For 
example, in Ghana, the private pharmaceutical sector supply medicines and medical supplies to the 
public facilities, NGOs and faith-based health care providers (Seiter & Gyansa-Lutterodt 2009).  
The pharmaceutical company is contacted to directly supply the hospitals, other health facilities and 
local pharmacies (Batliboi & Tambe 2014). In addition, private local pharmacies and drug stores supply 
medicines and medical supplies to a large proportion of the population in LMIC (Chua et al. 2013; 
Kagashe et al. 2011; Miller et al. 2016). 
Key challenges facing the public and PFP pharmaceutical sectors in LMICs  
Pharmaceutical sectors in LMIC are facing a lot of challenges, including inadequate funding, irregular 
drug supply, shortage of trained pharmacy service providers, issues with regulating the 
pharmaceutical system and many more (unpacked below). 
Access, availability and affordability  
In many African countries, irregular supply of medicines to health facilities is a common problem, and 
this has contributed to hindering the health system from achieving health equity for its population 
(Wales et al. 2014). Various studies have looked at the accessibility, affordability and availability of 
medicines in relation to health system outcomes (Bigdeli et al. 2012; Cameron et al. 2009; Hardon et 
al. 2006; Penfold et al. 2013). For example, a study found that in some African countries where 
antiretrovirals (ARVs) are free of charge, patients face barriers to access that include indirect cost like 
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transport, loss of work hours and long waiting times – which affect patients’ drug adherence and 
compliance (Hardon et al. 2006).  
Furthermore, in some part of rural Kenya, patients must travel long distances to get to the health 
facilities and pharmacies whereas drug shops are very close to their homes (Chuma et al. 2010).  Also, 
in some countries informal drug sellers can be the only available source of medicines (Chuma et al. 
2010). In Kenya patients had to buy medicines from drug shops because of stock out from government 
facilities and facility operation times as these facilities were mostly closed when their services are 
needed (Chuma et al. 2010). 
Drug stock out 
High inconsistency and unavailability of medicines in the health system has been reported by many 
studies (Bigdeli et al. 2012; Hardon et al. 2006; Schouten et al. 2011; Windisch et al. 2011).  For 
example, stock out of ARVs in Malawi (Schouten et al. 2011), stock out of medicines in Uganda 
interrupted antiretroviral therapy (ARTs) supply and drug adherence (Windisch et al. 2011), and rates 
of high stock out of essential medicines in most facilities in developing countries (Harding et al. 2013) 
affected patients’ drug adherence and negatively impacted the health system. Drug stock out can have 
negative impact on service delivery and the health system. For example, the maternity services in rural 
Tanzania was disrupted due to the lack of medicines in the facilities (Penfold et al. 2013) and Stock 
out of ARTs in public facilities impacts drug adherence and health outcome (Hardon et al. 2006). 
Human resource and training 
Having trained and equipped pharmacy professionals is necessary for the effective management of 
the supply chain and improved health outcomes. However, evidence from research have shown that 
in most developing countries procurement and drug supply chain are managed by individuals with no 
pharmacy training (Mackintosh et al. 2018). In another study, dispensing error was found to be 
common, in most cases medicines were dispensed with incorrect administration time or with no 
directive information, in others some of the prescribed medicines were not dispensed instead non-
prescribed medicines were dispensed (De Ar Rissato & Romano-Lieber 2013).  
In Ghana there is a huge difference in the access to medicines and provision of related pharmacy 
services between urban and rural communities (Owusu-Daaku 2002). For example, trained pharmacy 
personnel and pharmaceutical outlets are usually concentrated in the urban areas with the rural 
communities left with no option but to buy medicines from drug chemist and drug peddlers (Owusu-
Daaku 2002; Smith 2004).  
Part B: Scoping review  
9 
Regulation  
Many studies show that regulating the private sector can be complex and challenging (Bloom et al. 
2014; Green et al. 2010; McCabe 2009). This is of concern as most of population buy medicines from 
the private sector (Bigdeli et al. 2012). In addition, this can be seen in situations wherein international 
donors use NGOs procurement systems to supply medicines and related commodities to facilities and 
this may cause interruption in the supply chain resulting in delay, drug stock outs (Schouten et al. 
2011), duplication of medicines and waste of resources (Buse & Harmer 2007). Also, some donor 
organizations in LMICs decide on the brand of drug to be used (Clinton & Sridhar 2017), in a situation 
wherein the government is procuring a different brand or different strengths and dosages forms of 
the same drug this may result in challenges with drug administration thereby negatively affecting the 
health outcome of service users.  
In addition, in LMIC in some instances medicines donated can be close to expiration date or they may 
not (Van Dijk et al. 2011) be needed by the recipient country, so they are left piled up in the stores 
until they expire, and this can negatively affect health system (Berckmans et al. 1997; Bero et al. 2010; 
Igoumenidis et al. 2013; Van Dijk et al. 2011). It is therefore advisable for recipient countries to lay 
emphasis on things like county’s essential drug list, medicines with long expiration date and quality 
assured medicines (Hogerzeil et al. 1997; Obua et al. 2017; Pinheiro 2008).  
Finally, in some LMICs, the regulatory system is challenged with the lack of basic infrastructure, 
support for training and regulatory institutions such as laboratories of high-quality standards for 
quality assurance of pharmaceuticals (Mackintosh et al. 2018). Moreover, other studies have found 
that there is leakage of medicines from the private pharmaceutical providers to the informal sector 
(Brugha 2003) and this has raised concerns about the possibility of developing drug resistance such as 
antimicrobial and resistance to ARVs if the drug market is not controlled (Brugha 2003). 
Common interventions to strengthen the pharmaceutical supply chain  
In the face of these challenges there have been suggested solutions to improve the access to quality 
medicines and strengthen pharmaceutical systems – we have grouped these in the same clusters as 
the challenges above, but there is some overlap.  
Increasing access, availability and affordability 
Some studies showed that the standardization of treatment guidelines can improve the access and 
affordability of medicines (Bigdeli et al. 2012), for example, in Uganda the prescribing pattern for 
chronic diseases varies from one prescriber to the other and this can affect the cost of the medications 
based on the brand prescribed (Green et al. 2010). In addition, medicines can be made affordable to 
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the public through partnership between the public and private sector. For example, incentives can be 
given to private pharmacies for selling generic medicines which are cheaper as compared to the 
branded products to patients (Dovlo et al. 2016).  
Increasing financial access by implementing medical insurance schemes 
Medical insurance schemes have also been shown to contribute to improving access to quality 
medicines in many LMICs (Faden et al. 2011). For example, some medical insurance schemes cover 
the unemployed, most cover primary care level for both in and out patients and some also include 
non-prescription medication in the package (Carapinha et al. 2011). 
In addition, some authors suggest that medical insurance schemes can improve access to medicines 
by promoting generic medicines5 prescribing and negotiating with suppliers for medicine prices that 
are affordable by the poor and vulnerable (Faden et al. 2011). Also, a study looked at medical 
insurance schemes for those outside the formal work force because in most developing countries the 
population formally employed is usually just a hand full compared to those in local sector or the 
unemployed (Bennett et al. 1998). The schemes considered in the review are those that cover a wide 
range of conditions including essential medicines through risk sharing of the cost to prevent 
catastrophic payment and promote improved health outcomes (Bennett et al. 1998). 
Increasing regulation 
Regulating pharmaceuticals in LMICs can be enhanced with international support. For example, a 
study in some East African countries showed that the support they received externally with regards to 
medicines regulation have contributed greatly in reduction in counterfeit and substandard medicines 
in the market and improved access to quality medicines (Mackintosh et al. 2018). Also, the regulatory 
system of pharmaceutical supply can be strengthened through pharmacovigilance and post market 
surveillance of medicines and related commodities by the regulatory authorities (Bate et al. 2008; 
Hamilton et al. 2016).  For example, this process supported strengthening the pharmaceuticals in 
some African countries through post-market surveillance by testing quality of antimalarial medicines 
supplied to patients for identification of substandard and falsified antimalarials in the local 
pharmaceutical market (Bate et al. 2008). Evidence from such studies can also be used in educating 
patients on the dangers of counterfeit and substandard medicines (McCabe et al. 2011). 
                                                          
5 Generic medicine has the same dosage, strength, quality and route of administration of the brand name 
product. 
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Human resource empowerment  
There have been multiple interventions relating to strengthening pharmaceutical human resources. 
In Ghana, the Pharmacy Council, as a regulatory body for pharmacy practice trained and certified 
chemists and other drug sellers to address the shortage of pharmacists in country (Smith 2004). Again, 
studies have shown some improvement in service delivery in the pharmaceutical sector by 
empowering the work force, training improve these service providers in skill and knowledge and 
therefore enabling them to follow standard prescribing patterns, dispensing medications in correct 
dosage forms and strength (Smith 2004; Smith 2009).  
Table 1 presents a list of the documents included in the scoping review, as well as the challenges and 
interventions identified through each paper. This table is not comprehensive, and instead shows a 
selection of materials relating to LMIC pharmaceutical systems.  
 
Table 1: Pharmaceutical sectors in LMICs (challenges and interventions) 
Source; Author 
Reference and Title Country Findings 
Berman et al. 1993 
Consultation on the Private Health 
Sector in Africa 
Africa -Government support to private sector to reach their target goals.  
-Access barrier due to high expenditure on health care for the poor 
-Patient education and counselling 
-Monitoring private sector on quality, cost, equity and efficiency of 
services.  
-Influence of public or private practice on prescribing pattern 
-Reduction of subsidy to private services which are not cost effective 
and do not reach the most vulnerable population 
Gilson et al. 1994 
The potential of health sector non-
governmental organizations: policy 
options 
LMIC -Donated medicines supplied through NGOs  
-Some NGOs support the training of health workers 
-Services in hard to reach areas and target vulnerable groups 
-CHAM purchase medicines at a subsidized price from the CMS 
-CHAG exempted from import duties on pharmaceutical supplies 
Berman et al. 1995 
Non—governmental health care 
provision 
Kenya -Dispensaries a higher percentage of for PFP services 
-Community pharmacies key in rural areas (in immunization, common 
childhood illnesses and contraception) 
Berman et al. 1995 
Zambia: Non-governmental Health 
Care Provision 
Zambia -Training of private pharmacists by government 
-Government supply medicines to private facilities 
-Pharmacies provides services for common illnesses and contraception 
-Pharmacies restricted to urban areas 
-FBHPs concentrated in the rural areas than public services. 
-Huge amount of household expenditure on health care is on medicines 
Bennett et al. 1997 
Public -private roles in the 
pharmaceutical sector: Implications 
for equitable access and rational 
drug use    
Global -Improved access to essential medicines and rational drug use  
-Huge resources spent on medicines in LICs 
-Drug expenditure account for highest amount of out of pocket 
payment 
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Brugha et al. 1998 
Improving the quality of private 
sector delivery of public health 
services: challenges and strategies 
Asia, Africa 
and Latin 
America 
-Polypharmacy and antibiotics prescription 
-Prescription pattern dependent on whether it private or public 
-Lack of regulatory control in LMICs 
-Patients education and continuous training for service providers 
De Waal et al. 2005 
Turning of the tide:  A Qualitative 
study of SACBC Funded antiretroviral 
treatment programmes 
South Africa -ARVs availability motivates service providers because of improved 
patient’s heath outcome 
-Patient capacity and vulnerability affect ARVs compliance 
Buse et al. 2006 
Seven habits of highly effective 
global public- private health 
partnerships: Practice and potential 
Global -Supply medicines for free or at a reduced cost to the communities 
-Poor transparency and effective communications 
-Poor harmonization resulting in waste and duplication of supplies 
-Vertical procurement of medicines by global fund and GAVI result in 
delay disbursement and stock out 
Goudge et al. 2009  
Affordability, availability and 
acceptability barriers to health care 
for the chronically ill: Longitudinal 
case studies from South Africa 
South Africa -Patients seek care from informal drug sellers and or traditional healers 
due prolong stock out at government facilities 
-Patients lost to follow up due to regular drug stock out 
Kulkarni et al. 2009 
Pharmacoeconomic: An emerging 
branch in health sciences for decision 
making  
 
LMIC -Relationship between cost of medicines and patient drug compliance 
-Educating prescribers on importance on cost effective prescribing on 
patient health outcomes 
-State subsidized medicines lower the cost of medicine in the market 
-Effect of various channels of drug purchase on drug cost 
Carapinha et al. 2011 
Health insurance systems in five sub-
Saharan African countries medicines 
benefits and data for decision making 
Ghana, 
Kenya, 
Nigeria, 
Tanzania & 
Uganda 
-Some medical scheme caters for the unemployed 
-Non-prescription medicines being paid for by insurance schemes 
-Burden of cost sharing on patients 
-Delays in settling claims by insurance 
-Limitation to medicines benefits 
-Lack of transparency and fraud 
Faden et al. 2011 
Active pharmaceutical management 
strategies of health insurance 
systems to improve cost effective use 
of medicines in LMIC: A systematic 
review of current evidence 
LMIC -Insurance helps in improving access to pharmaceuticals in LMICs  
-Need to negotiate for lower drug prices with private suppliers 
-Need to promote generic prescribing 
 
McCabe et al. 2011 
Private Sector Pharmaceutical Supply 
and Distribution Channels in Africa: A 
Focus on Ghana, Malawi and Mali 
Ghana, 
Malawi and 
Mali 
-Regulation of pharmaceutical sector varies according country 
-Shortage of pharmacy personnel and lack training for health workers 
-Lack of resources to run pharmacy business 
-High informal drug market attributed to poverty, drug stock out and 
lack of knowledge on the dangers of counterfeit and substandard 
medicines by consumers 
Bigdeli et al. 2012 
Access to medicines from a health 
systems perspective 
Global -Increase in ownership of pharmacy outlet by health professionals.  
-Patients prefer the private health sector 
-Resources from sale of medicines used to fund the rest of the health 
system 
-Medicines availability build trust between health workers, patients and 
the community 
Wigle 2013  
Human papillomavirus (HPV) vaccine 
implementation in low and middle-
income countries (LMICs): Health 
system experiences and prospects 
LMIC -Donors negotiating for lower vaccine prices to increase access in LMICs 
-Donors (GAVI Alliance and GAP) act as lobbyist 
 
Bigdeli et al. 2014 
Medicines in Health Systems: 
Advancing access, affordability and 
appropriate use 
LMIC -Strengthened accountability and transparency of pharmaceuticals 
-Rational drug use and improved equitable access. 
-Understanding the relationship between medicines and the other 
building blocks of the health system 
Bloom et al. 2014 LMIC -Poor regulation of medicines in the market and need for better 
regulatory system 
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Innovation in regulation of rapidly 
changing health markets 
-Protecting patients through price regulation and import restriction 
Penfold et al. 2014 
Staff experiences of providing 
maternity services in rural southern 
Tanzania – a focus on equipment, 
drug and supply issues 
Tanzania -Drug stock out negatively impacted health outcome of patients. 
-Reduced staff morale  
-Broken trust in the health system by service users 
Russo et al. 2014 
On the margins of aid orthodoxy: the 
Brazil-Mozambique collaboration to 
produce 
essential medicines in Africa 
Mozambique -Local drug production supported by international donors 
-Training pharmacy personnel in drug production 
-Improved access to ARVs 
 
Wales et al. 2014 
Stock-outs of essential medicines in 
Tanzania 
 
Tanzania -Regular drug stock out and poor access to essential medicines 
-Lack of funding for medicines and delay in disbursement in the public 
sector 
-Weak governance structure 
Prinja et al. 2015 
Availability of medicines in public 
sector 
Health facilities of two North Indian 
States 
India -High out of pocket payment for medicines 
-Regular stock out of medicines 
 
Settumba et al. 2015 
The health system burden of chronic 
disease care: an estimation of 
provider costs of selected chronic 
diseases in Uganda 
Uganda -Drugs supplied at no cost at public facilities. 
-Chronic medication drugs available at higher level health facilities only  
-Regular stock out of medicines 
-Patients buy medicines from private pharmacies when the facilities run 
out of medicines 
De Jongh et al. 2016 
Barriers and enablers to integrating 
maternal 
and child health services to antenatal 
care in low and middle-income 
countries 
LMIC -Training service providers on the use treatment guidelines 
-Stock out and irregular supply of medicines as a barrier to achieving 
heath systems goals 
Dolvo et al. 2016 
Policy dialogue- the “bolts and joints” 
of policy-making: experiences from 
Cabo Verde, Chad and Mali 
Cabo Verde, 
Chad and 
Mali 
-Knowledge sharing and exchange of experiences 
-Incentives given to private pharmacies to dispense generic medicines 
-Promotion of equitable access to medicines 
Hamilton et al. 2016 
Public health interventions to protect 
against falsified medicines: a 
systematic review of international, 
national and local policies 
LMIC -Strengthened medicine regulatory authority in LMIC 
-Pharmacovigilance and post-market surveillance 
-Ongoing training and supportive supervision on drug quality 
assessment and management. 
-Consumer education on false and substandard medicines 
Workneh et al. 2016 
Assessment of health challenges and 
opportunities for possible integration 
of diabetes mellitus and TB services 
in South- Eastern Amhara Region, 
Ethiopia.   
A qualitative study 
Ethiopia -Drug stock out due to lack of coordination between stakeholders 
-Sell of households to sell possessions to pay for medicines 
-Inclusion of antidiabetic medicines in the essential medicines list 
Mwita et al. 2017 
Availability of prescribed medicines 
for elders at Sekou-Toure Regional 
Hospital in Mwanza, Tanzania 
Tanzania -Fee exemption policy for elderly patients on chronic medication 
improved compliance and health outcomes 
-Lack of knowledge about the free medication policy for elderly 
patients by the Tanzanians 
 
 
Conclusion 
This review shows a set of key characteristics about different types of pharmaceutical systems in 
LMICs. The different types of sectors in pharmaceutical systems can generally be divided into public 
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and private, and the private is further subdivided into PFP and PNFP. These sectors are very important 
in health system strengthening because of their key roles in ensuring access to quality medicines and 
pharmaceutical services. Furthermore, the contribution of the different pharmaceutical actors in the 
supply chain and the interconnections between public and private (PFP and PNFP) pharmaceutical 
sectors shows that it is important for them to work in collaboration to achieve the desired health 
outcomes.  
Common challenges include: inadequate funding, drug stock outs and irregular supplies, shortage of 
trained pharmacy personnel and lack of system for drug regulation and quality assurance. Possible 
(more common) interventions include the use of standardized treatment guidelines, implementation 
of medical insurance schemes to improve access to medicines and involvement of international 
donors to support in improving drug regulation. Also, the collaboration between government and the 
private pharmaceutical sector is seen to play a key role in improving access to quality affordable 
medicines.  
Finally, the scoping review identified the important role PNFP drug supply chain potentially plays in 
patient health outcomes and health systems strengthening. It also showed that within the PNFP 
sector, there is a particularly interesting and potentially relevant cluster – the pharmaceutical supply 
chains and systems supported by FBHPs. There is a massive evidence gap (that is, they appear 
potentially important, but little is actually known about them). In addition, it is important to 
understand how these FB-DSOs pharmaceutical supply chains fit within their national pharmaceutical 
systems. 
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chains and their functioning within African pharmaceutical systems: A 
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Abstract 
For the health system to function well, the population must have equitable access to quality affordable 
pharmaceutical supplies. Pharmaceutical systems in Africa are challenged by inadequate funding, drug 
stock outs and irregular supplies, a shortage of trained pharmacy personnel and a lack of systems for 
drug regulation and quality. Faith-based health providers, as a component of the private-not-for-profit 
sector, have long been involved in the supply of   pharmaceuticals to complement public sector efforts 
in wider coverage of communities in Africa. However, their role in the pharmaceutical systems has 
never been examined or clarified. This study aims to examine the nature and function of faith-based 
health care providers in providing access to pharmaceutical supplies in the African context. We 
conducted an exploratory qualitative systematic review across multiple electronic databases to 
identify documents that contain information on faith-based involvement in pharmaceutical supply in 
Africa. Citation tracking was used to identify further relevant articles. The review identified 1550 
documents. After removing duplicates and excluding articles (due to lack of access or relevance), 20 
articles were included in the review. These were analyzed using thematic narrative analysis. The 
analysis revealed that there is a major evidence gap relating to private-not-for-profit, faith-based 
contribution to African pharmaceutical systems. Faith-based drug supply organizations are extensive 
and contribute to national pharmaceutical systems but there is very little known about them. They 
have been in existence for a long time providing pharmaceutical supplies to both rural and urban areas 
mainly targeting rural remote areas. The review found that faith-based drug supply organizations 
improved access to medicines and related commodities. There is also clear potential for a positive 
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contribution in improving quality assurance of pharmaceuticals by FB-DSOs but in some cases, there 
is a lack of regulation. Faith-based involvement in pharmaceutical systems improved access for the 
general population and inserted additional pharmaceutical supplies into the national pharmaceutical 
system – thereby strengthening the broader public-private partnership between faith-based providers 
and the public sector. The analysis confirmed that faith-based involvement in pharmaceutical supply 
chains contributes to strengthening the national health system by complementing the public 
pharmaceutical system through improved access to medicines and related commodities in Africa. 
Key words 
Health system, pharmaceutical system, pharmaceutical supply, drug supply, medicine supply, supply 
chain, Africa, faith-based 
Key messages 
• Faith-based involvement in pharmaceutical supply chains in Africa is extensive and contributes 
significantly to national pharmaceutical systems.   
• There is little evidence about how faith-based engagement in pharmaceutical supply chains 
contributes to or detracts from national supply chains. 
• However, available evidence suggests that faith-based engagement in pharmaceutical supply 
chains contributes to national pharmaceutical supply chains and national health systems.   
• Partnerships are needed between government and faith-based drug suppliers in the 
pharmaceutical sector to improve access, address financial challenges and create a sustainable 
source of financing for pharmaceutical systems in Africa. 
 
 
Introduction 
Pharmaceutical systems play an important role in health care delivery. Strengthening the 
pharmaceutical sector to meet the needs of the population is important in achieving positive health 
outcomes (Hafner et al. 2016; World Health Organization 2007). The low availability and reduced 
access to medicines and related commodities in low- and middle-income countries (LMICs) is of great 
concern (Bigdeli et al. 2012; Cameron et al. 2009; Chuma et al. 2007; Wales et al. 2014). 
In Africa, pharmaceutical services are provided by public and private providers – the public services 
are usually provided by government, and the private services by a mix of private-for-profit (PFP) and 
private-not-for-profit (PNFP) providers – the latter including non-government organizations (NGOs), 
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local and international donors and faith-based health care providers3 (FBHPs) (Patouillard et al. 2007) 
(see Figure 1 below). Recently, there has been much discussion on how working with the private 
pharmaceutical sector and incorporating their services into the national pharmaceutical services can 
improve access to quality affordable medicines (Palmer et al. 2003; Quick et al. 2002). However, the 
contributions of FBHPs in the pharmaceutical supply chain is not well recognized or well documented 
(Banda et al. 2006; Olivier et al. 2012b; Schmid et al. 2008). Isolated reports mention that the nature 
and function of FBHPs takes different forms from drug procurement, distribution (Lamberts & 
Hogerzeil 1984) dispensing (Rookes 2010) and quality assurance testing (Kawasaki & Patten 2002; 
Petersen et al. 2017), to name but a few. Understanding the various ways in which FBHPs are involved 
in drug supply chains in Africa is important for health systems strengthening. Across all LMICs, FBHPs 
are predominant in Africa – where about 23 of the 54 African countries are known to have substantial 
FBHP sectors (Dimmock et al. 2012; Dimmock et al. 2017; Olivier et al. 2015; Whyle & Olivier 2017). It 
is also in Africa where the most is known and published about FBHPs (in comparison with other LMICs). 
Within that literature, there is some mention of ‘faith-based’ pharmaceutical services, supply chains 
and networks. For example, Banda et al. (2006) produced an important report for the World Health 
Organization (WHO) on supply and distribution of pharmaceuticals by faith-based organizations in 
Sub-Saharan Africa. Schmid et al. (2008) have also noted the presence of pharmaceutical networks 
and stores in many African countries. Others have noted that missionaries were sometimes the first 
providers of basic pharmaceutical stores and services in the era before modern public health systems 
(Kawasaki & Patten 2002; Olivier et al. 2012b). However, initial scoping review shows an alarming 
absence of any substantive evidence about the current presence and functioning of this particular 
type of PNFP within African health systems (see Part B) – although It is commonly assumed they are 
substantial and important (Chirwa et al. 2013; McCabe et al. 2011; Rookes 2010). While research on 
FBHPs in relation to other aspects of health care services is growing (Duff & Buckingham 2015; Grieve 
& Olivier 2018; Olivier & Wodon 2012a), their specific role in pharmaceutical supplies is not well 
understood. 
 
                                                          
3 Faith-based health care providers- refers to all the different health care services provided by faith-based 
organizations while FB-SOs is only for those involved in the pharmaceutical supply chain 
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Figure 1: Nature of the pharmaceutical system showing the position of faith-based health care providers (Source Author) 
 
In Africa, challenges faced by the public pharmaceutical sector4 cannot be overemphasized, and this 
renders the sector ill-equipped to meet the needs of the population (Bigdeli et al. 2013; Harding et 
al. 2013; Hardon et al. 2006). Specifically, resource-poor settings are faced with unreliable funding, 
which leads to irregularity of drug supply, frequent drug stock-outs, lack of infrastructure and 
inefficient management with neglect of regulation of medicines and related commodities (Bigdeli et 
al. 2012; Harding et al. 2013; Kohler et al. 2012; Wales et al. 2014). When these challenges are not 
addressed, patient drug compliance and adherence drop, negatively impacting on health outcomes 
(Hamers et al. 2013; Kangwana et al. 2009; Reardon 2014). 
 It is evident in many African countries that irregular supply of medicines to government health 
facilities is a common problem, and this has contributed in holding back the health system from 
achieving health equity for its population (Wales et al. 2014; Chuma et al. 2010; Schouten et al. 
2011). Stock out of medicines in most developing countries interrupted antiretroviral therapy (ARTs) 
supply and drug adherence in most facilities in developing countries thereby impacting the health 
system negatively (Schouten et al. 2011; Windisch et al. 2011; Harding et al. 2013). For example, a 
study in Tanzania revealed that drug adherence and patient health outcome was negatively 
impacted by the shortage of medicines in public health facilities (Penfold et al. 2013; Hardon et al. 
2006). Also, in Kenya patients sometimes buy medicines from drug shops because of unavailability of 
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medicines from government facilities (Chuma et al. 2010) while in other instances informal drug 
sellers are the only available source of medicines (Chuma et al. 2010). These medicine stores have 
long operating times as compared to government facilities that are mostly closed when their 
services are needed (Chuma et al. 2010).   
In another study, it was found that in some African countries where antiretrovirals (ARVs) are free of 
charge, patients are unable to benefit from the services due to barriers to access that include indirect 
cost like transport, loss of work hours and long waiting times (Hardon et al. 2006). 
The shortage of pharmaceutical professionals in health facilities is also a cause for concern 
(Mackintosh et al. 2018), and may contribute to long waiting times at facilities, thereby discouraging 
patients from attending health facilities and increasing the likelihood of drug noncompliance and 
drug resistance (Hardon et al. 2006). The regulatory system in some LMICs lack basic infrastructure, 
high quality standard laboratories for quality assurance of pharmaceuticals and human resource 
expertise (Mackintosh et al. 2018). In another study it was revealed that medicines leak from the 
private pharmaceutical sector to the informal market in developing countries and this is of great 
concern as this will increase the chances of developing resistance to antimicrobials and ARVs 
(Brugha 2003). 
It is important to note that no pharmaceutical system is a purely public entity because in every 
pharmaceutical supply chain there is some private entity involvement whether it is pharmaceutical 
companies producing medicines, or logistics companies transporting medicines (Bennett et al. 1997; 
Mackintosh et al. 2011).  
The private pharmaceutical sector plays an important role in the drug supply chain (Bennett et al. 
1997; Hanson et al. 2008). In LMICs, it is estimated that 66% of prescribed medicines are sourced from 
private facilities while 35% of prescribed medicines are found in the public facilities (Cameron et al. 
2009). Pharmaceutical supply chains can be improved through partnerships between government and 
the private sector (Bustreo et al. 2003; Prata et al. 2005), and such partnerships can increase access 
to quality medicines at affordable cost (Bigdeli et al. 2014).  
As noted earlier, there is a cluster of PNFP pharmaceutical providers in Africa that are defined as ‘faith-
based’. It has been argued in the literature (although not well evidenced) that these are important as 
they are known to have good access in remote and rural areas where there are few pubic services 
(Green 2008) – and are said to have different drug supply sources (often importing medicines from 
overseas through international nongovernmental organizations (NGOs) or purchasing medicines from 
the local manufacturing companies or the central medical stores (Dowling 2011).  
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Certainly, it is obvious from the literature that the public or government pharmaceutical sector cannot 
provide the needed medicines and medical supplies and associated services for the whole population 
(Berman & Hanson 1993; Berman et al. 1995a). Therefore, the government pharmaceutical sector 
must engage with faith-based drug supply organizations to improve access to quality affordable 
medicines (Chirwa et al. 2013; Gilson et al. 1994). This can be done through tax exemption on 
medicines, or the supply of free or subsidized drugs to faith-based organizations (Gilson et al. 1994). 
However, the shortage of evidence on the exact extent, nature and function of FBHPs involved in 
pharmaceutical supply chains in Africa (noted above) hinders efforts to strengthen national 
pharmaceutical supply systems through engagement with FBHPs. The aim of this exploratory 
qualitative systematic review study is to begin to fill this evidence gap – collating and synthesizing 
descriptive qualitative and quantitative evidence from the published literature about, a) the 
(presence/extent) of FBHP-pharmaceutical supply chains, b) common characteristics of (diverse types 
of) FB-pharmaceutical supply chains, and c) how faith-based actors involved in pharmaceutical supply 
chains fit within their broader national pharmaceutical systems.  
Method  
An exploratory qualitative systematic literature review was undertaken to explore the available 
literature on the extent, nature and function of faith-Based drug supply organizations (FB-DSOs) 
involved in pharmaceutical supply chains in Africa. The review included all types of data, qualitative 
and quantitative – as a synthesis approach was necessary given the exploratory research question. To 
strengthen this systematic review, an initial scoping review was done to understand the existing 
pharmaceutical systems in low- and middle-income countries (LMIC), and the challenges faced by 
these systems and possible interventions to improve their functioning.  
The scoping review also served to inform the development of the search strategy for the systematic 
review. The search strategy was then refined based on previous searches. Standardized subject terms 
and natural language terms were used so that studies of the same concept using different relevant 
terminology will be included in the results (Hammerstrøm et al. 2010). Databases searched in this 
review included PubMed, EBSCOhost (Africa-wide information and Cumulative Index to Nursing and 
Allied Health Literature (CINAHL)) and Web of Science. These databases were included to minimize 
bias and to retrieve the full range of available documents. For adequate specificity and sensitivity, 
search terms were grouped into three categories using Boolean operators.  
The main search terms for the systematic review are outlined in Appendix B. The search strategy for 
each database is found in Appendix C. The documents identified from these databases were then 
exported to Endnote and citation tracking of all included documents was done to capture all additional 
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relevant documents, and those found relevant to the study were included in the review. Only 
documents in the English-language which discussed the nature and function of FB-DSOs in drug supply 
chains were included in the study (Table 1). Both peer-reviewed and grey literature were included 
(McAuley et al. 2000; Shea et al. 2007). The inclusion of grey literature ensured that documents from 
non-academic sources were included while also minimizing bias (McAuley et al. 2000). The geographic 
area for this study is Africa and the names of all countries within the African continent were included. 
Only documents that provided information on financing, access5, regulations, human resource and 
training of FBDSOs in pharmaceutical supply chain in Africa were included. 
Table 1: Systematic review inclusion criteria 
Inclusion Exclusion 
Discuss the nature and function of FB-DSOs in 
pharmaceutical supply chain  
Discuss FBHPs in healthcare but not pharmaceutical supply 
chain  
Contains information on drug financing, access, regulation 
and human resources in FB-DSOs pharmaceutical supply 
chain  
FB-DSOs and government pharmaceutical supply chain 
considered as one entity 
Africa  Outside Africa  
English  Non-English  
Table 1: Systematic review inclusion criteria 
 
The study aims to answer the research question by using thematic analysis to classify the data.  From 
the scoping review in part B themes were identified and these themes will be used to inform the 
coding process.  
A data extraction table was used to record and synthesize the information extracted from the papers 
(Tranfield et al. 2003) to minimize bias while ensuring that the process is standardized throughout. A 
draft of the data extraction table is found in Appendix A. The data extraction table was used as a guide 
for the analysis process and to facilitate data management which can be used for reference and by 
future researchers. All articles that met the selection criteria (Table 1) were read and analyzed in the 
same way to ensure that enough information is extracted to be able to answer the research question 
as accurately as possible. Thematic analysis is a method widely used and suitable for reviews, using 
wide range of source of information (Mays et al. 2005). This method is a good choice for this review 
since the involvement of FB-DSOs in pharmaceutical supply is not well researched (Braun & Clarke 
2006). 
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Figure 2: Search flow chart (Source Author)
Results: Characteristics of included documents 
The initial search of the different databases yielded 1550 documents in total. When duplicate items 
were excluded, this was reduced to 1189 documents. When the search was modified to screen 
citations by title and abstracts, 1151 documents were further excluded. These articles were excluded 
for lack of relevance to the study, particularly those from non-African countries. A total of 38 articles 
were finally selected for detailed reading and analysis. 
Total citation retrieved during 
database searches
(n=1550 )
Relevant articles selected for 
screening 
(n=1189)
Full texted articles assessed 
for eligigibility
(n=38)
Articles and documents that 
met inclusion(12) plus 2 from 
citation tracking
(n=14)
Additional search on Google 
and Google scholar yielded
(n=6)
Articles for inclusion in review
(n=20)
Articles and document 
unavailable and or rejected as 
not appropriate for study
(n=26)
Ineligible and excluded 
articles after screening by 
title and abstract:
(n=1151)
Duplicates removed
(n=361)
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Full text for six of the documents were unavailable and 20 were rejected because they were not 
appropriate for the study. These included studies that mentioned FB-DSOs in general but did not 
specifically comment on pharmaceutical supply and others, that considered faith-based and 
government drug supply services as a single entity. In total, 12 articles and documents met the 
inclusion criteria and two additional documents were retrieved from citation tracking resulting in a 
total of 14 documents. Further searches on Google and Google Scholar yielded six extra documents 
from grey literature, bringing the overall total to 20 documents included in this review (Figure 2). Given 
that this is a small number, a full presentation of each of these is provided (Table 3).   
Geographic distribution of articles  
The review found a good representation of studies in Africa – studies from 14 countries (Burkina Faso, 
Cameroon, Ivory Coast, Mali, Malawi, Nigeria, Ghana, Zambia, Tanzania, Kenya, Uganda, Democratic 
Republic of Congo (DRC), Rwanda and South Africa) were eligible for inclusion. Ghana has the highest 
number of studies (6), followed by Malawi and Uganda (4), Cameroon (3), DRC and Nigeria (2), and 
the rest of the countries with one (Table 3). Two articles reported on multi-country studies: Banda et 
al. (2006) reported on Cameroon, DRC, Ghana, Kenya, Malawi, Nigeria, Rwanda, South Africa, 
Tanzania, Uganda, Zambia; and Petersen et al. (2017) reported on Cameroon, DRC, Nigeria, Kenya, 
Uganda, Ghana). One study reported on a case study in Kenya and Uganda (Kawasaki & Patten 2002), 
while two others reported on Africa in general (Ecumenical Pharmaceutical Network 2016; Kareen 
Shawa-Duran 2017).  Another study considered developing countries (Rookes 2010). The geographic 
location of the studies according to region is shown in Table 2.  
Table 2: Geographic distribution of included studies 
Region  Number Distribution within region 
West Africa  11 Burkina Faso (1), Ghana (6), ivory coast (1), Mali (1), Nigeria (2), 
Southern Africa  7 Malawi (4), South Africa (1), Zambia (2)  
East Africa  4 Kenya (1), Uganda (4),   Rwanda (1), Tanzania (1) 
Central Africa  5 Cameroon (3), Democratic Republic of Congo (2) 
Note: some studies reported on more than once country, hence the disparity in number 
Source: Author 
 
Year, religion and research types  
Studies included in the review span from 1984 to 2017, covering a period of 33 years, with similar 
findings and minimal differences in methodologies (Table 3). Figure 3 demonstrates that the bulk of 
the research was completed recently, indicating that this topic is increasingly being focused on and 
that there is a growing interest in faith-based programmes at community level. All the FB-DSOs in 
the review were of the Christian faith, with no information on organizations affiliated with Islam or 
other religions identified. Both qualitative and quantitative studies were identified for inclusion, with 
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methods ranging from case studies, reports, surveys, laboratory testing, questionnaires, interviews, 
and observations. 
 
 
Figure 3: Included studies by year of publication 
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Table3: Summary of included studies (N=20) 
 
Reference  Country / 
region 
Role/position in 
pharmaceutical 
supply chain 
Themes 
Financing Access, affordability and 
availability 
Regulation and quality 
assurance 
Human resource and 
training 
Stock outs 
Lambert et 
al. 1984 
Ghana Dispensing, 
procurement 
Donor funding, drug 
sales 
Supply in rural areas    
Asenso-
Okyere 
1995 
Ghana Medicines supplied 
in rural areas 
Poor do not pay for 
medicines 
    
Gilson et al 
1995 
Tanzania Dispensing Not specified High stock levels of medicines and 
medical supplies, no contraceptives 
 Understaffed Irregular supply of vaccines 
Grimaud 
1998 
Ivory Coast Dispensing Consultation fees, drug 
sales, reduced 
government support 
donor support 
Decrease in patient turn out due to 
high cost 
  Drug shortages 
Aids action 
1999 
Burkina 
Faso  
Procurement  
dispensing  
Donor funding  ARVs and related medicines 
dispensed for free 
   
Kawasaki et 
al. 2002 
Kenya, 
Uganda  
Procurement, supply  Donor funding, 
medicines sales  
Good stock level, better access, 
expensive 
 Training by MEDS  
Andrews 
2004 
Ghana  Procurement, 
dispensing  
 Dispense for free for poor, 
dispense at affordable cost 
Adheres to prescribing regulation    
Banda et al. 
2006 
Multi- 
country  
supplied in rural 
areas 
Donor funding, 
medicine sales  
Medicines dispensed at affordable 
cost or free 
Non-compliance with drug 
regulatory body 
  
Lum et al. 
2007 
Nigeria  ART, related 
medicines supply, 
home care visit 
Donor funding  Medicines supplied for free    
Ballou Allou 
-Aaeres et 
al. 2008 
Ghana, 
Zambia  
Dispensing  Donor funding, 
Government support, 
medicines sale 
Medicines supply in rural areas at 
no cost  
   
Carlucci et 
al. 2008 
Zambia  Dispensing  Government support, 
donor funding 
Supply ART free    
Njozing et 
al. 2010 
Cameroon  Dispensing  Medicines sale Supply ART and Cotrimoxazole    
Rookes 
2010 
Developing 
countries 
Dispensing  Donor funding, 
government support, 
medicines sale 
Medicines supplied at no cost      
Irregularity of medicines supply 
McCabe et 
al. 2011 
Ghana, 
Malawi, 
Mali 
Procurement, 
dispensing 
Donor funding, 
government, medicines 
sale 
Supply drugs free, co-payment by 
medical insurance schemes 
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Reference  Country / 
region 
Role/position in 
pharmaceutical 
supply chain 
Themes 
Financing Access, affordability and 
availability 
Regulation and quality 
assurance 
Human resource and 
training 
Stock outs 
EPN 2016 Africa Capacity building, 
advocacy 
 Supply medicines and related 
commodities to faith-based and 
public facilities at affordable cost 
Quality assurance testing, on 
adherence to treatment 
guidelines 
Training of pharmacy 
staff 
 
Kareen 
Shawa-
Durand 
2017 
Africa  Training   Improved access to medicines due 
to increase trained personnel 
 Training of pharmacy 
personnel 
 
Khuluza et 
al. 2017 
Malawi Procurement, 
dispensing 
Donor funding, 
medicines sales 
High stock level, free medicines for 
poor, drug costly 
Pass quality assurance test  Low stock of antibiotics, stocks 
out of quinine injection 
Khuluza et 
al. 2017 
Malawi  Quality assurance 
testing  
  Pass quality assurance test   
Kibira et al. 
2017 
Uganda  Stock level  Medicines sales Medicines are supplied at a lower 
price than in government facilities 
 
  High number of stock outs 
Petersen et 
al. 2017 
LMIC/ 
multi-
County 
Quality assurance 
testing 
Donor funding  Falsified and substandard 
antimalarial medicines found in 
Cameroon, DRC and Nigeria 
private sectors 
Training of pharmacy 
personnel 
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Christian Health Association Sierra 
Leone (CHASL) 
Established: 1975 
Nature and extent: owned by CHA with 
a pharmaceutical supply system who are 
said to Provide services to almost ~30% 
of the population 
 
  
 
  
 
 
Bureau des Formations Medicales Agreee du Rwanda 
(BUFMAR) 
Established:1975  
Nature and extent: owned by Catholic and Protestant 
Churches who are said to supply  
Christian Social Services Commission (CSSC) 
Tanzania 
Established: 1992 
Nature and extent: owned by Tanzania 
Episcopal Conference (TEC) and Christian 
council of Tanzania (CCT) who are said to serve 
679 dispensaries across Tanzania  
Joint Medical Stores (JMS) 
Established: 1980 
Nature and extent: FB-DSO owned by 
Uganda Catholic and Protestant 
Medical Bureau supplying 14 
dispensaries 
Mission for Essential Drugs Supplies (MEDS) 
Established: 1986 
Nature and extent: owned by Christian health 
association of Kenya (CHAK) & Kenya 
Episcopal Conference (KEC) who are said to 
serve 680 dispensaries across Kenya 
 
Catholic Drug Centre (CDC) Ghana 
Established: 1983 
Nature and extent: FB-DSO run and 
owned by Catholic church, supplying 
Catholic FBHPs nationally, who are said 
to provide supply to 36 catholic hospitals 
and 78 clinics of health services in Ghana  
 
 
 
Christian Health Association Nigeria (CHAN)  
Established: 1979 
Nature and extent: FB-DSO owned by the Catholic 
Bishop and Christian council of Nigeria with six drug 
depots for supply of medicines and related supplies 
across Nigeria. 
Eglise évangélique du Cameroun, EEC in 
Cameroon  
Established: 1986 
Nature and extent: owned by Protestant 
and Catholic Churches  
 
 Christian Health Association of Malawi 
(CHAM) 
Establishment: 2000 
Nature and extent: owned by CHA who are 
said to serve 12 dispensaries across Malawi  
Zimbabwe Health Association of Churches related hospitals 
(ZACH) 
Established: 1974 
Nature and extent: owned by the heads of churches in 
Zimbabwe with a pharmaceutical supply system who are said 
to provides services to ~ 45% of health facilities 
Christian Health Association Zambia (ZAC) 
Nature and extent: owned by CHA with a 
pharmaceutical supply system who are said to 
provide services to ~ 40% of health facilities and 
they are mainly present in the rural areas 
Eglise du Christ au Congo-Direction des Oeuvres 
Medicale (ECC-DOM) 
Established: 1994 
Nature and extent: owned by Protestant medical 
mission who are said to provide services to ~40% 
of health facilities in DR Congo 
Figure 4: Mapping the DSOs in Africa 
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Extent and characteristics of faith-based drug supply organizations (FB-DSOs) 
In this study these organizations are commonly referred to as faith-based drug supply organizations (FB-DSOs). 
Drug supply organizations are faith-based health care providers involved in the pharmaceutical sector only – 
procurement, supply, human resource training and quality assurance (Kawasaki & Patten 2002). FB-DSOs are 
drug supply organizations operating under or affiliated to a Christian Health Association (CHA). CHAs are 
national networks of FBHPs that are common in Africa. The supply of pharmaceuticals is part of the services 
that are provided by CHA. Some of the articles included in the review presented very little information on the 
extent of FB-DSOs because most of these articles were reporting on the health care service delivery as a whole 
(Table 2). The FB-DSOs identified in the review include Joint Medical Stores (JMS) in Uganda, Mission for 
Essential Drugs and Supplies (MEDS) in Kenya, Christian Social Services Commission (CSSC) in Tanzania, 
Catholic Drug Centre (CDC) in Ghana, Christian Health Association Malawi (CHAM), Christian Health 
Association Nigeria, (CHAN), Christian Health Association Zambia (CHAZ), Christian Health Association Sierra 
Leone (CHASL), Bureau des Formations Médicales Agréées du Rwanda (BUFMAR), Eglise du Christ au Congo - 
Direction des Oeuvres Médicales (ECC-DOM), Eglise évangélique du Cameroun (EEC) and Zimbabwe 
Association of Churches related Hospitals (ZACH) (Banda et al. 2006; Schmid et al. 2008) (Table 4 and Figure 
4).  
Some of these organizations are members of EPN (Ecumenical Pharmaceutical Network), a Christian 
organization supporting churches and church health systems in improving access to quality affordable 
pharmaceuticals while promoting the use of medicines rationally (Ecumenical Pharmaceutical Network 2016). 
EPN is reported to be involved in lobbying and advocacy, increasing access to antiretroviral drugs (ARVs), 
human resource empowerment, fighting against antimicrobial resistance through rational drug use and 
consumer education (Ecumenical Pharmaceutical Network 2016; Kareen Shawa-Duran 2017). For example, it 
is reported that EPN coverage on ARV services in Kenya decreased the viral load and improved patient’s health 
outcomes (Green 2008). EPN has wide coverage of members including 32 CHAs and 18 FB-DSOs (Ecumenical 
Pharmaceutical Network 2016). Table 4 presents the FB-DSOs identified for this study. 
The ownership of FB-DSOs varies and includes: Catholic and Protestant Churches of Malawi, Rwanda and 
Cameroon; Catholic Bishop, Christian Council of Nigeria and the North Medical Advisory Council of Nigeria; 
Ghana Catholic Bishops Conference, Christian council of Ghana  and Ghana Pentecostal Council; Council of 
Churches in Sierra Leone; Medical Committee of the Christian Council and the health department of Zambia 
Episcopal Conference of Zambia; Tanzania Episcopal Conference and Christian council of Tanzania; Catholic 
and Protestant Medical Bureau of Uganda; Christian Health Association of Kenya and Kenya Episcopal 
Conference; Protestant medical mission of Democratic  Republic of  Congo; and Head of Christian 
Denomination in Zimbabwe (Kawasaki & Patten 2002; Odumosu et al. 2009; Schmid et al. 2008). Of the FB-
DSOs outlined in Table 4 and Figure 4, nine were supported entirely through donor funds, while five also 
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received national government funding, and a further nine used sales of medicines as an additional revenue 
stream. Some FB-DSOs are networks owned by collaborations between different denominations (Olivier et al. 
2012b). For example, CDC is owned by the Catholic Health Service of Ghana and supplies medicines to the 
hospitals and clinics owned by the Catholic denomination (Dimmock et al. 2017; Grieve & Olivier 2018).  
Financial donations from (local and international) funders is a major source of funding for FBHPs in Africa 
(Olivier et al. 2015). This is also true for FB-DSOs as most of them benefit from donations (Table 4). In addition 
to donations some FB-DSOs have financed their supply chain through medicines sales (Kawasaki & Patten 
2002; Olivier et al. 2015) and mark ups (Grieve & Olivier 2018). Again, many FB-DSOs also receive support from 
national government to improve access to medicines and related commodities (Table 4) (Kawasaki & Patten 
2002; Khuluza & Heide 2017; Olivier et al. 2012b).  
Some FB-DSOs have been in existence as far back as 1971, when ECC-DOM was established, while newer FB-
DSOs were established as recently as 2000 (Banda et al. 2006; Schmid et al. 2008), (see table 4). Certain FB-
DSOs run a pharmaceutical supply chain mainly for FBHPs facilities in a country, such as Malawi (McCabe et 
al. 2011; Rookes 2010); while others perform the functions of central medical stores, procurement 
organizations, and suppliers to public and private non-faith organizations (Kawasaki & Patten 2002; Odumosu 
et al. 2009). For example, JMS and MEDS in Uganda and Kenya respectively, are FB-DSOs with a wide customer 
coverage (Kawasaki & Patten 2002) and CHAN pharm in Nigeria supplies pharmaceuticals not only to FBHPs 
facilities but also to the public and the PFP pharmaceutical sector (Odumosu et al. 2009). The services of these 
FB-DSOs are present in both urban and rural areas (Banda et al. 2006; Rookes 2010) but they mainly target 
remote and hard-to-reach areas (Banda et al. 2006) and are therefore located in rural and remote areas where 
government services are not readily available (Banda et al. 2006; Grant et al. 2011). FB-DSOs are generally 
known to supply medicines and related commodities at no cost, or at no cost to the poor and at affordable 
prices for the rest of their patients (Asenso-Okyere 1995; KhuluzaFelix & Heide 2017; Rookes 2010).  Six papers 
identified in this review supplied medicines at no cost, while five provided medicines free of charge only to 
the poor. However, the cost of pharmaceuticals supplied by some FB-DSO were reported to be higher than 
normal market price (Kawasaki & Patten 2002; Kibira et al. 2017). 
 
Table4: Drug supply organizations in Africa 
Name of network/ 
organization and 
country 
Date of 
establishment 
Ownership  Known pharma supply 
(default self-estimated 
market share of linked 
facilities))  
Funding sources 
(all partial) 
References 
Eglise du Christ au 
Congo - Direction 
des Oeuvres 
Médicales (ECC-
DOM) 
1971 
 
Protestant medical 
mission 
40% health services in DRC Not specified Aembe et al 
2017 
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DRC 
 
Zimbabwe 
Association of 
Churches related 
Hospitals (ZACH) 
Zimbabwe 
1974 Head of Christian 
denominations 
Provides 45% of health care 
services 
Donations, user 
fees and sale of 
medicines 
Gwati 2015 
Bureau des 
Formations 
Médicales Agréées 
du 
Rwanda 
(BUFMAR) Rwanda 
 
1975 Catholic and Protestant 
Churches 
 
Provides ~35% of health care 
in Rwanda 
Donations, 
government 
Mustapha et 
al 2009 
Schmid et al 
2008 
Christian Health 
Association of 
Sierra Leone 
(CHASL) 
Sierra Leone 
1975 Head of Churches in 
Sierra Leone 
Provides 30% of health care 
services 
Donations, drug 
sales 
Witter et al 
2012 
Christian Health 
Association of 
Nigeria (CHAN 
Pharm) 
Nigeria 
1979 Catholic Bishop’s 
Conference, Christian 
Council of Nigeria, 
Northern Christian 
Medical Advisory Council 
6 drug depots 
[400 mission hospitals, 4000 
PHC facilities]   
Donations, 
wholesales of  
essential 
medicines & 
supplies 
Odumosu et 
al 2009 
Larbi et al 
2004 
 
Joint Medical Stores 
(JMS) 
Uganda 
1980 Uganda Catholic Medical 
Bureau (UCMB) & 
Uganda Protestant 
Medical Bureau (UPMB) 
44 dispensaries Donations, 
government, 
drug sale 
Reinikka et al 
2010 
Kawasaki et  
al 2002 
Catholic Drug 
Centre (CDC) 
Ghana 
1983 Ghana Catholic Bishops 
Conference, Christian 
Council of Ghana  
Ghana Pentecostal 
Council 
 
Supply medicines to 36 
hospitals and 78 clinics 
 
Donations, drug 
sales, mark-ups 
Dimmock et al 
2017 
Gilson et al 
1995 
McCabe et al 
2011 
 
Mission for 
Essential Drugs and 
Supplies (MEDS) 
Kenya 
1986 
 
 
 
Christian health 
association of Kenya 
(CHAK) & Kenya 
Episcopal Conference 
(KEC) 
680 dispensaries Donations, 
government, 
drug sales 
Kawasaki et al 
2002 
Blevins et al 
2014 
Christian Social 
Services 
Commission (CSSC) 
Tanzania 
1992 
 
Tanzania Episcopal 
Conference (TEC) and 
Christian council of 
Tanzania (CCT) 
697 dispensaries Donations, drug 
sales 
Häfele-Abah 
& Neuhann 
2010, 
Samwel 2015 
Eglise évangélique 
du Cameroun,  
(EEC) 
Cameroon 
1994 Evangelical Church of 
Cameroon 
Serve 39 dispensaries Not specified Yadav et al 
2011 
Affordable 
medicines for Africa 
(AMFA) 
South Africa 
1997 No evidence 
 
AMFA work in partnership 
with RTT in providing 
medicines and related 
services for communities 
and townships outside cape 
town 
 Owens et al 
2009 
Christian Health 
Association of 
Zambia (CHAZ) 
Zambia 
1999 Medical Committee of 
the Christian Council of 
Zambia and the health 
department of the 
Zambia Episcopal 
Conference 
[40% of health care in 
Zambia] 
 
Donations, drug 
sales 
 
Yadav 2007 
Ballou-Aaares 
et al 2008 
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Note: The text in italics are estimates based on facility coverage. Due to the limitation of data we were unable retrieve validated data 
on actual coverage for some FB-DSOs. 
  
Common characteristics of FB-DSOs  
This section discusses the findings with respect to access; availability; affordability; drug stock-outs; human 
resources and training; and regulation in relation to the nature and function of FB-DSOs in Africa.  
Access, availability and affordability  
Both JMS and MEDS are described as having better access to medicines since they usually have good stock-
levels of medicines and related commodities (Kawasaki & Patten 2002). In Malawi, CHAM facilities dispense 
medicines for free to the poor and those who can afford to pay are charged less than what PFP facilities are 
charging (Khuluza & Heide 2017; McCabe et al. 2011; Rookes 2010). In addition, some FB-DSOs worked hard 
to improve the provision of antiretroviral therapy and related commodities to HIV-positive patients. For 
instance, in Burkina Faso, a small Christian organization worked with government and donor funding 
organizations to provide ARVs and other medicines used to treat opportunistic infections12 for HIV-positive 
patients (AIDS action 1999). Another study in Zambia reported on FB-DSOs providing antiretroviral (ARVs) for 
HIV-positive patients whose drug adherence was tested on non-ART medicines (Carlucci et al. 2008). These 
patients were found to be compliant to follow-up appointments and adherent to ART, irrespective of the 
distance they had to cover (Carlucci et al. 2008). For example, based on the study on ART adherence in Zambia 
this is what Carlucci et al (2008) observed; 
Most patients travelled 3 or more hours each way, often on foot; yet, most were able to achieve 
optimal adherence in their first months of therapy (Carlucci et al. 2008, p. 6). 
Access to medicines and related commodities is critical in the vision of FB-DSOs and was found to be superior 
over most government facilities (Gilson et al. 1995; Khuluza & Heide 2017).  
Church facilities had significantly higher scores than other groups for drug availability. Thus, for 
example, there was a 90% chance of their having chloroquine, and a 70% chance of having penicillin 
constantly available (Gilson et al. 1995, p. 109).  
We noted minimal variations in the services provided by FBHPs. Given that FBHPs have funding support from 
multiple donors and national governments, they appear to be homogenous in their operations with better 
                                                          
12 Opportunistic infections are infections occurring frequently and are more severe in people with weak or depressed 
immune systems.  
Christian Health 
Association of 
Malawi (CHAM) 
Malawi 
2000 Catholic and Protestant 
Churches in Malawi 
12 dispensaries Donations, In-
country resource 
mobilization, 
drug sale 
Khuluza et al 
2017 
Gilson et al 
1995 
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access to medicines and related commodities than the government sector (Carlucci et al. 2008; Lum et al. 
2007; McCabe et al. 2011). In Nigeria, for example, FBHPs were able to provide medicines and related HIV-
services to patients as a result of the support from the President's Emergency Plan for AIDS Relief (PEPFAR) 
and other funding organizations (Lum et al. 2007). Again, in Malawi, CHAM facilities are sometimes supported 
by international donors or government, resulting in them being able to dispense medicines and related 
commodities for free to the poor or at a minimal cost (McCabe et al. 2011).  
In general, medicines and related commodities are affordable and accessible at FBHPs because they usually 
have good stock levels and dispense medicines for free in most facilities. In some cases, the poor receive free 
supply and a minimal amount is paid by the rest of the population (AIDS action 1999; Asenso-Okyere 1995; 
Ballou-Aares et al. 2008; Carlucci et al. 2008; Ecumenical Pharmaceutical Network 2016; Lum et al. 2007; 
Rookes 2010). For example, Rookes 2010 study on FBHPs in developing countries revealed that;  
Treatment in (church health services) CHS facilities was in the past generally free for everyone, because 
the bulk of the funds came from overseas’ churches (Rookes 2010, p. 256)  
However, the review revealed evidence of challenges faced by some FB-DSOs in providing accessible and 
affordable pharmaceuticals. For example, a reduction in support from government and donor organizations 
was found to result in patients paying for medicines and related commodities at FBHPs (Grimaud 1998; Kibira 
et al. 2017; Rookes 2010). A study in Burkina Faso found that the medicines dispensed, and services provided 
by some FBHPs were unaffordable for some categories of patients, especially the poor (Grimaud 1998). 
Similarly, patients seeking services at FB-DSOs in Malawi and Uganda were required to pay as a result of 
fluctuations in donor funding and irregular and insufficient support from government (Kibira et al. 2017; 
Rookes 2010). In another example, in the Ivory Coast, services provided by FBHPs were found to be negatively 
affected by dwindling donor support and irregular drug supply from governments (Grimaud 1998).  
Regulation  
Findings from the review showed that FBHPs are involved in motivating for medicines quality assurance 
ensuring that pharmaceuticals in their facilities and elsewhere are of good quality and comply with 
recommended quality standards (Kawasaki & Patten 2002; Khuluza et al. 2017; Petersen et al. 2017). For 
example, a study which conducted testing for falsified and substandard13 medicines in the pharmaceutical 
market in Malawi, found that all the medicines in selected facilities of FBHPs in the were of acceptable quality 
(Khuluza et al. 2017). In another study, the FBHPs were involved in quality assurance testing of medicines in 
the pharmaceutical market in a few African countries (Petersen et al. 2017). This method of quality assurance 
                                                          
13 Falsified medicines contain the wrong pharmaceutical ingredients as specified by the manufacturer, while 
substandard medicines usually contain the correct pharmaceutical ingredients but not in the same quantity as specified 
by the manufacturer.  
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was able to identify falsified and substandard products in the pharmaceutical market in Cameroon, DRC and 
Nigeria (Petersen et al. 2017) 
Within the seven countries included in this survey, the highest proportion of substandard and falsified 
medicines was found in Cameroon (total 15 out of 212 samples = 7.1%), followed by the Democratic 
Republic of Congo (2.7%) and Nigeria (1.1%). As mentioned, the true number of poor-quality medicines 
is likely to be even higher than detected in this study (Petersen et al. 2017, p. 17). 
 
Human resource and training  
Studies in the review found that providing training and supervision for the staff involved in the drug supply 
chain can yield positive results (Gilson et al. 1995). The review revealed that MEDS has worked with EPN to 
train pharmacy staff involved in the handling of medicines and related commodities (Kawasaki & Patten 2002). 
Also, pharmacists and pharmacy technicians working in FBHPs were trained on how to use minilab to test for 
falsified or substandard medicines locally (Petersen et al. 2017). 
“A German pharmacist acted as trainer in the first workshops, while in the subsequent trainings 
personnel from the previously trained organizations acted as trainers. The persons trained in the local 
drug supply organization for use of the Minilab were mostly pharmacists, pharmacy technicians or 
assistant pharmacists, and they were usually supported by an unskilled worker in the Minilab 
operation” (Petersen et al. 2017, p. 7). 
The EPN reported involvement in pharmaceutical capacity building processes to improve access to quality 
medicines and services and improved health outcomes (Ecumenical Pharmaceutical Network 2016). For 
example, it is reported that EPN promotes the empowerment of pharmacy personnel and other prescribers in 
improving rational drug use and addressing the issue of antibiotic misuse and antimicrobial resistance 
(Ecumenical Pharmaceutical Network 2016; Kareen Shawa-Duran 2017).  
Between 2011 and 2017 a total of 56 candidates from 9 countries, South Sudan, DRC, Cameroon, 
Kenya, Uganda, Tanzania, Ghana, Chad, and Zambia, have been supported by the ESP initiative. To 
date, over 90% of candidates from hospitals in disadvantaged areas were enrolled for training that led 
to successful completion and awarded a recognized pharmacy qualification (Kareen Shawa-Duran 
2017, p. 3)  
Discussion   
 Our systematic review of the analysis of the role of FB-DSOs in the pharmaceutical supply chains in Africa 
found strengths and limitations for each of the themes on pharmaceutical supplies. FB-DSOs tend to lack 
published data on their role in pharmaceutical supplies in Africa, however, available evidence suggests that 
FB-DSOs in the pharmaceutical sector better serve poor and vulnerable populations and improve availability 
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of pharmaceutical supplies in difficult-to-reach areas. Our review indicated that FB-DSOs, as a component of 
the private pharmaceutical sector, play a key role in health service delivery through improved access to 
medicines and related commodities, thereby contributing to health systems strengthening. This section 
describes the ways in which FB-DSOs can and do contribute to strengthening national health systems, through 
their capacity to meet the challenges faced by national pharmaceutical systems. In addition, this section 
suggests some ways in which the contribution of FB-DSOs can be better harnessed to strengthen national 
pharmaceutical systems.  
Faith-based pharmaceutical system actors’ role in meeting the challenges faced by national pharmaceutical 
systems 
We are now going to look at access, affordability and availability; human resources and extent of FB-DSOs, 
because of their important role in the national pharmaceutical supply and the health systems strengthening.  
Access, affordability and availability  
FB-DSOs embody unique strengths with respect to access, affordability and availability which can help to 
strengthen national pharmaceutical supply systems. However, they are also faced with challenges which 
curtail their progress. Many authors have highlighted that the public health sector in LMICs face numerous 
challenges including poor financing, inadequate resources and a lack of infrastructure, which contribute to 
unreliable pharmaceutical stock-levels in health facilities and irregularities in pharmaceutical supplies in 
health facilities (Cameron et al. 2009; Chuma et al. 2007; Chuma et al. 2010; Wales et al. 2014). The review 
showed that access to medicines and related commodities is critical in the vision of FB-DSOs and much of the 
evidence suggests that the faith-based sector provides better access than most government facilities (AIDS 
action 1999; Asenso-Okyere 1995; Gilson et al. 1995; Khuluza & Heide 2017). As a result, community 
members may be compelled to seek health care from FB-DSOs and avoid government facilities with high 
stock-out of   pharmaceuticals (Hardon et al. 2006; Schouten et al. 2011; Wales et al. 2014).  
In LMICs, patients often must pay for medicines and pharmaceutical supplies when other services in the 
facilities are provided at no cost (McKee et al. 2006) because medicines are being purchased from the local 
PFP pharmaceutical sector (Bennett et al. 1997; McKee et al. 2006) due to high stock out of supplies at 
government facilities (Harding et al. 2013). Significantly, the review found that while FB-DSOs do also purchase 
medicines and related commodities from the local PFP pharmaceutical sector, they often exempt the poor 
patients from paying for drug supplies (Khuluza & Heide 2017; Rookes 2010). For example, in Malawi and 
Ghana medicines and related commodities are purchased from the local private pharmaceutical sector when 
there is delay or interruption in supply and in such situations, the poor receive the medicines for free while 
the rest of the population pay for their medicine supply (Andrews 2004; Khuluza & Heide 2017; Lamberts & 
Hogerzeil 1984; Rookes 2010). This is important in achieving the desired health outcomes as existing evidence 
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from LMICs have shown that improving access to medicines through fees exemption improves patient drug 
adherence and strengthens the health system (Mwita et al. 2017; Prinja et al. 2015).  
On the other hand, we found in this review that some patients would have to pay for medicines in some FB-
DSOs facilities (Grimaud 1998; Kibira et al. 2017). Evidence in this review indicated that patients seeking health 
care at FB-DSOs in Burkina Faso and Uganda paid for medicines because donor funding and government 
support were insufficient to cover the running cost of the facilities (Grimaud 1998; Kibira et al. 2017). The 
review also found some evidence of medicines being sold at higher prices in FB-DSOs. While a study from 
Malawi found medicines prices at FB-DSOs were lower than the international reference price (Khuluza & Heide 
2017), the cost of medicines at faith-based facilities in Uganda was found to be higher than the international 
reference price (Kawasaki & Patten 2002; Kibira et al. 2017). This is likely to hinder the contribution of FB-
DSOs to the national health system because the cost of medicines will serve as a barrier to access due to 
unaffordability by the patients.  
Some countries have already moved to free services provided by government health facilities (Abiiro et al. 
2014; Chuma et al. 2009; Ridde & Morestin 2010), thus asking patients to pay for medicines and consultation 
fees does not align with the priority of most national governments. This can be problematic when patients 
cannot afford to pay, and FB-DSOs are the only form of health care service available, thereby limiting access 
to medicines for (mainly) poor patients (Gilson et al. 1994; Olivier et al. 2015). For example, in Uganda, FB-
DSOs charge for medicines (Kibira et al. 2017) while medicines are dispensed for free in public health facilities 
(Ridde & Morestin 2010). Some studies found that the poor are benefiting from the FBHPs more than rich who 
can afford to go to the PFP sector (Nazerali et al. 2006; Ridde & Morestin 2010). 
FBHPs have been recognized for their contribution to the management of HIV/AIDS in Africa, especially about 
the drug supply system (El-Sadr et al. 2012; Olivier et al. 2012b). Although this review did not focus on 
HIV/AIDS, a few studies in the review concentrated on FB-DSOs involvement in the supply of ARVs (AIDS action 
1999; Carlucci et al. 2008; Lum et al. 2007; Njozing et al. 2010). This shows that FB-DSOs play an important 
role in providing ARVs during a time in which the African continent faces a high burden of disease because of 
the HIV/AIDS epidemic (World Health Organization 2013). 
Faith-based health care providers contributed to improved access to maternal health medicines and related 
commodities. However, some health facilities had very small or irregular supply of medicines and related 
commodities for reproductive health (Kibira et al. 2017), while others did not stock contraceptive medicines 
or provide family planning services (Gilson et al. 1995). This can be attributed to religious views concerning 
contraception and the association of certain contraceptives with risky behaviours (EP Network 2016; World 
Health Organization 2008). Given that access to contraceptives is an important function of any health system, 
the failure of some FB-DSOs to ensure this, is a significant shortcoming. 
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Human resources  
This review found little information on human resource management, which is surprising because we know 
from other literature that this is an important issue (Mackintosh et al. 2018; Prata et al. 2005; Smith 2004; 
Smith 2009; Van Damme et al. 2008). In LMICs, the pharmaceutical supply chain is mostly managed by non-
pharmacy professionals (Mackintosh et al. 2018), and this sometimes results in the wrong medicines being 
dispensed with errors in drug dosages and administration times (De Ar Rissato & Romano-Lieber 2013). 
Evidence shows that training of pharmacy personnel in knowledge and skills enables them to follow standard 
prescribing and dispensing patterns of pharmaceuticals to promote better service delivery (Smith 2004; Smith 
2009). In this review, only five out of the 20 papers referred to the training of pharmacy personnel (Ecumenical 
Pharmaceutical Network 2016; Gilson et al. 1995; Kareen Shawa-Duran 2017; Kawasaki & Patten 2002; 
Petersen et al. 2017). Some papers had very little information on training, for example, a study on Tanzanian 
primary health care only made mention of supportive supervision and training being provided for pharmacy 
personnel annually (Gilson et al. 1995). This review noted that EPN is working with FB-DSOs to empower 
pharmacy personnel through training programmes in a number of African countries (Ecumenical 
Pharmaceutical Network 2016; Kawasaki & Patten 2002). This is a significant contribution, as a lack of trained 
pharmacy professionals contributes to the issue of irrational drug use and incorrect drug dispensing (Kareen 
Shawa-Duran 2017). 
Extent of FB-DSOs  
It is commonly assumed that FB-DSOs make a significant contribution to overcoming national pharmaceutical 
system challenges because they are responsible for a large proportion of drug dispensing facilities. However, 
while some information in the review supports this claim, evidence is severely limited. The information on the 
extent or ‘reach’ of FB-DSOs in the included articles is relatively limited (Carlucci et al. 2008; Grimaud 1998; 
Kibira et al. 2017) since most articles reported on the general services provided by FB-DSOs and did not provide 
in-depth detail on medicine supply (Carlucci et al. 2008). It was also unclear whether these FB-DSOs were 
members of the FB-DSOs in their country as information about ownership and how long they have been 
operating was unavailable (AIDS action 1999; Carlucci et al. 2008; Grimaud 1998; Njozing et al. 2010). 
However, broader grey literature (not included in this review) provides further evidence of the extent of FB-
DSOs activity. For example, we know that in Kenya and Tanzania 15.8% and 11% of dispensaries are served by 
FB-DSOs respectively (Blevins & Griswold 2014; Häfele-Abah & Neuhann 2010). FB-DSOs are known to serve a 
high proportion of dispensaries across different African countries (Table 4). There is also evidence from the 
grey literature that there are dispensaries, mostly in rural areas, across the different countries in Africa served 
by FB-DSOs (CHAM 2019; MEDS 2019; ECC 2019).  The validated data for dispensaries served by FB-DSOs for 
some countries was unavailable because some countries use primary health care to comprise of health 
centres, dispensaries and health post and at the end a single figure is given for all of them (Dimmock et al. 
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2017; Lijdsman et al. 2004). In Rwanda, for example, it is reported that BUFMAR provides 35% of primary care 
service (Dimmock et al. 2017). Also, in Ghana, it was evident that CDC contributed greatly to the 
pharmaceutical supply chain, however, in the literature, we found figures for the number of hospitals and 
clinics (Dimmock et al. 2017; Grieve 2018; Yeboah & Buckle 2017). It is likely that the dispensaries are included 
in the number of catholic facilities stated in some of the literature (36 hospitals and 78 clinics). In Nigeria also, 
the literature was clearer on the number of drug depots (six depots) available across the country and then 
they further stated that the medicines and related commodities are supplied to the hospitals and clinics from 
these different depots based on catchment area (CHAN 2019). 
Table5: Dispensaries served by public and FB-DSOs 
Country  FB-DSOs dispensaries  
Kenya  680 
 Malawi   12 
 Rwanda  39 
Tanzania 680 
 
Source (Blevins et al 2014, Häfele-Abah & Neuhann 2010, CHAM, Reinikka et al 2003). 
Researchers could not find validated data for other countries 
  
We also know that 42.5% of all ARVs, 15.6% for malaria services and 64.3% for TB services provided by 
FBHPs is funded by Global Fund (Haakenstad et al. 2015). FBHPs also provide a significant and well-
coordinated programme for HIV positive patients that are on treatment in African countries facing a high HIV 
burden (Blevins & Griswold 2014). Therefore, while the extent of FB-DSOs is not verifiable in complete detail, 
the broader literature suggests that FB-DSOs are making a substantial contribution to improving access to 
medicines and related commodities and strengthening the pharmaceutical sub-system and the health 
system. 
Faith-based organizations have contributed to several other programmes in addition to pharmaceutical 
supplies and health care delivery broadly. The training of health care personnel is one such programme which 
has assisted in strengthening the health work force through improved service delivery, thereby strengthening 
the health system. There are varying numbers of training facilities in different African countries: Nigeria (28), 
Kenya and Tanzania (24), DRC (20), Uganda (19), Zimbabwe (14), Zambia (9), and Cameroon (3) (Dimmock et 
al. 2017). We were unable to identify the availability and number of training institutions for Sierra Leone and 
Rwanda from the literature (Table 5). Zimbabwe has 14 mission hospitals for training nurses (ZACH 2019), 
while in Malawi, CHAM has well- established training institutions for health care providers, which account for 
approximately 80% of the human resource for health training in Malawi (CHAM 2019).  
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Table6: Faith-based training institutions training health workers in Africa   
Countries  Number of faith-based training facilities  
 Cameroon  3 
Democratic Republic of Congo 20 
U Ghana  12 
Kenya    24 
Malawi  10 
 Nigeria  28 
 Rwanda  Not specified  
Sierra Leone Not specified  
Tanzania 24 
Uganda  19  
Zambia  9 
Zimbabwe  14 
Source compiled by author based on data from Dimmock et al 2017 and CHA websites of the different countries   
 
FB-DSOs are resilient and- continue to provide services in the face of health system shocks 
FB-DSOs are working toward making medicines and related commodities accessible to the poor and 
marginalized populations (Olivier et al. 2012b; Schmid et al. 2008). For example, in Ghana, CHAG facilities 
are usually in operation when the national health system is on strike because they believe in providing a 
non-stop service for populations in need (Yeboah & Buckle 2017). In another instance, in Ghana, patients 
were referred to CHAG facilities by government stakeholders when government-employed pharmacists were 
on strike (Yeboah & Buckle 2017). This indicates that FB-DSOs can continue to provide services when the 
public sector is on strike. Furthermore, the services of FBHPs have been found to be in full operation when 
the public pharmaceutical supply chain is challenged with stock-outs. For example, a CHAM facility in Malawi 
decided to buy medicines from the PFP pharmaceutical sector when they could not receive their supply in 
time from the CMS, to have e medicines to dispense to patients (Chirwa et al. 2013). In Rwanda, in times of 
supply stockouts at the CMS, BUFMAR is viewed as the source of supply for the public pharmaceutical supply 
chain, thereby complementing the national pharmaceutical supply system (Lijdsman et al. 2004). 
This paper has shown that FB-DSOs have the capacity to overcome the significant challenges faced by 
national pharmaceutical systems. In the following section, we present a few mechanisms through which this 
capacity can be better harnessed by national health systems –public private partnerships (PPP)s and 
improved regulation. 
The need for public private partnership 
Partnership between government and the private pharmaceutical sector (PFP and PNFP) is key in improving 
the pharmaceutical supply chain and strengthening the health system in LMICs (Bennett et al. 1997; Berman 
et al. 1995a; Bustreo et al. 2003; Gilson et al. 1994; Palmer 2000).  Evidence from the literature shows that 
the collaboration between government and NGOs has been successful in several countries (Berman et al. 
1995a; Gilson et al. 1994; Zafar Ullah et al. 2006). For example, in Bangladesh, improved access and 
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compliance to tuberculosis medicines was achieved through collaboration between government and an NGO 
(Zafar Ullah et al. 2006).  
There is evidence that partnerships between government and FBHPs also helps to strengthen the 
pharmaceutical supply chains of FBHPs. For example, many PNFP pharmaceutical organizations buy medicines 
from government at subsidized rates, some PNFP organizations benefit from duty-free entry on importation 
of medicines (Gilson et al. 1994; McPake & Hanson 2016), and others receive medicines and other support 
from the ministry of health to provide services to poor and vulnerable populations (Chirwa et al. 2013). 
This review found that partnerships between government and FB-DSOs should be viewed as crucial since FB-
DSOs provide services to the poor and vulnerable by filling in the gap, where there are inefficiencies on the 
side of the public sector (Banda et al. 2006). It is also evident from the review that most of the FB-DSOs receive 
support from government and in most instances, this is in the form of medicines and pharmaceutical supplies. 
In other words, it is the partnership between the FB-DSOs and government that enables FB-DSOs to supply 
medicines for free (AIDS action 1999; Carlucci et al. 2008; Lum et al. 2007). For example, in Malawi, CHAM 
facilities dispense medicines received from government at no cost to the patient, while patients must pay for 
medicines procured from the private sector, except for the poor (Khuluza & Heide 2017). The review also 
found that in Ghana, FBHPs procure medicines from the CMS (Ballou-Aares et al. 2008; McCabe et al. 2011), 
enabling them to dispense these medicines to populations in need.  
Available literature has shown that the informal sector is highly utilized by the poor, either because they are 
cheaper or the only available source of medicines that supply rural remote areas and operate for longer hours 
(Chuma et al. 2007). Partnerships between FB-DSOs and government may address the issue of the informal 
sector by ensuring that the services of FB-DSOs are available in rural and hard-to-reach areas as supported by 
this review (Asenso-Okyere 1995; Carlucci et al. 2008). 
Evidence from several studies found that the private pharmaceutical sector is the main source of 
pharmaceuticals and preferred by most patients over the public pharmaceutical sector, in LMICs (Berman et 
al. 1995a; Patouillard et al. 2007; Smith 2009). Drug stock-outs are prominent in the public sector in LMICs 
with less than 35% of the prescribed medicines available in public facilities, while the rest is sourced from the 
private pharmaceutical sector (Cameron et al. 2009). As stated earlier, the review shows that FBHPs have 
better stock of pharmaceuticals (Gilson et al. 1995; Khuluza & Heide 2017). Therefore, partnerships between 
government and FB-DSOs pharmaceutical supply chain could improve access to pharmaceuticals, strengthen 
pharmaceutical systems and improve health outcomes. 
The need for improved regulation 
Part C – Journal Article 
26 
The published studies reported that regulatory standards can improve quality of care and efficiency 
(Mackintosh et al. 2011). In some LMICs, the pharmaceutical regulatory system is challenged by a lack of basic 
infrastructure, a shortage of expertise or training facilities, and a scarcity of high-quality standard laboratories 
for quality assurance of pharmaceuticals (Mackintosh et al. 2018). However, some evidence collected in this 
review indicates that the faith-based pharmaceutical sector can help national systems to overcome these 
challenges. 
For example, MEDS demonstrated involvement in quality assurance of medicines and other pharmaceutical 
products supplied to their customers and patients (Kawasaki & Patten 2002). In another study in the review, 
FBHPs participated  in quality assurance of medicines in the local private pharmaceutical sector in a few African 
countries with support from international donors (Petersen et al. 2017).  
Evidence from the broader literature has also shown that regulating the private pharmaceutical sector is a 
huge task (Green et al. 2010), and this review showed that FB-DSOs have similar weaknesses in record 
keeping, quality assurance of medicines and compliance with drug regulatory bodies (Banda et al. 2006; 
Njozing et al. 2010). The review also found that none of the FBHPs dispensing pharmaceuticals reported that 
these products were tested for quality assurance before being dispensed to the patients, which is 
particularly problematic for facilities that source their pharmaceutical supplies directly from international 
donors (AIDS action 1999; Lamberts & Hogerzeil 1984). Strengthening government monitoring and 
regulatory systems to ensure that essential drug lists are adhered to, medicines are quality assured and 
resources received by health care providers are accounted for, is vital  (Bennett et al. 1994; Hogerzeil et al. 
1997; McPake & Hanson 2016; Obua et al. 2017; Pinheiro 2008). Detailed assessment of the quality of the 
medicines supplied at FBHPs facilities is essential to ascertain the quality of medicines patients receive, and 
this will help inform policy makers and other stakeholders in decision-making in order to provide the 
required support to maintain and improve the drug supply chain.  
Finally, memoranda of understanding are an important mechanism to regulate the relationship between 
partners. However, none of the studies in the review reported on the existence of a memorandum of 
understanding or contract between government and FB-DSOs or between FB-DSOs and international donors. 
This is problematic because the presence of a contract usually specifies the duties and expectations of both 
parties and this makes it possible to keep track of implementation processes (Rookes 2010). 
Limitations  
This review is limited by the fact that it only includes English-language publications, which might have led to 
the exclusion of relevant documents published in other languages.    
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The focus on Africa excludes literature on FB-DSOs involved in pharmaceutical supply systems from the other 
contexts such as Asia (India) and the Oceania (Papua New Guinea). Findings, from this review cannot be 
generalized outside Africa, which highlights the need for more research in other regions.  
This review did not include input from stakeholders or experts in the study area which would have been 
relevant as they would have been able to provide a perspective on the relationship between the policy makers 
and the FB-DSOs in Africa.  
The literature search is limited to databases that are accessible through the University of Cape Town (UCT), 
although significant efforts were made to access unavailable materials by direct communication with authors 
or requesting materials from publishers. A few documents were rejected due to lack of access to the full text.  
Conclusion  
Pharmaceutical systems play an important role in health systems strengthening. The pharmaceutical supply 
chains in Africa are challenged with inadequate financial resources, stock of pharmaceutical supplies, shortage 
of trained pharmacy personnel and lack of infrastructures and a system for the for proper functioning of the 
drug regulatory system. The supply chain can be strengthened through partnership between the public and 
PNFP (FB-DSOs) pharmaceutical sectors.   
FB-DSOs play a key role in the provision of pharmaceutical supplies and related health care services (Banda et 
al. 2006; Schmid et al. 2008; World Health Organization 2007). However, very little evidence is available on 
their involvement in pharmaceutical supplies. This review identified a limited number of studies in countries 
known to have well-functioning FB-DSOs working in the pharmaceutical supply chain in Africa. The data 
describing the role and function of FB-DSOs in the pharmaceutical supply chain in Africa is limited, an 
indication that further research is needed on how the engagement with FB-DSOs can contribute to health 
system strengthening in Africa.  
FB-DSOs exist and are making significant contributions to national pharmaceutical systems. Their supply 
services cover both urban and rural areas but are mainly focused on the rural and hard-to-reach areas. Also, 
the supply of pharmaceuticals is not limited to faith-based facilities but extends to the public and private 
pharmaceutical sector as well. FB-DSOs have good drug stock-levels with improved access to pharmaceutical 
supplies when compared to that of government facilities. They are therefore often able to supply 
pharmaceuticals at no cost, making their services well-trusted by a large proportion of the population. 
However, some FB-DSOs involved in the pharmaceutical sector are faced with challenges - including financial 
constraints from the global recession and dwindling support from international donors - compelling facilities 
to introduce fees for service with significant implications for availability, affordability and accessibility of 
pharmaceutical supplies. Further research on funding is required to look at the specific funding interests of 
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donors and to outline factors leading to donor fatigue and the impact of this on beneficiaries, particularly, in 
the context of pharmaceutical supplies in Africa. 
FB-DSOs working in the pharmaceutical sector play an important role in empowering pharmacy personnel with 
the sole aim of improving access to medicines through proper prescribing, dispensing and promoting rational 
drug use. However, limited evidence on human resource management was noted, and this highlights the need 
for more research in this area, to provide answers on how human resources are managed within FB-DSOs. 
Some FB-DSOs are seen to play a key role in supporting the quality assurance testing of medicines in the PFP 
pharmaceutical market in Africa. On the other hand, others were found to be deficient in record keeping, 
quality assurance of medicines and compliance with medicine regulatory bodies especially for the medicines 
dispensed by FB-DSOs, which are mostly received from international donors. Improved monitoring and 
regulation by government through partnerships with FB-DSOs and promoting rational drug use to ensure 
equitable and affordable access to quality medicines is critical. There is a need for further research into the 
quality of medicines dispensed to patients by FB-DSOs in Africa.  
The review confirmed the important role FB-DSOs play in the pharmaceutical supply chain to complement the 
national pharmaceutical system by improving access to medicines and related commodities thereby 
contributing to national health system strengthening. 
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Appendix A: Review Data table 
 
References  Country/region Method DSO 
involvement 
Partnership 
involvement 
Role/position 
in pharma 
supply chain 
Financing Access Quality Affordability Regulation Stock outs Training  
LAMBERTS et 
al 1984. 
Ghana Questionnaire  Yes Not 
specified 
Quantification, 
procurement 
and supply of 
medicines to 
mission 
hospitals and 
clinics.   
Medicines 
donated by 
international 
donors. 
Facilities pay a 
minimal 
amount for the 
medicines to 
raise funds to 
purchase 
medicines 
Procurement 
of cheap 
essential 
medicines 
that can be 
easily 
transported 
to remote 
areas 
increased 
access to 
medicines 
    
  
ASENSO-
OKYERE, W. K. 
1995 
Ghana 
 
Not 
specified 
Not 
specified 
Providing 
medicines in 
rural areas at 
an affordable 
cost or at no 
cost for the 
poor 
 
The poor 
receive 
medicines 
and other 
services for 
free at 
mission 
facilities 
known to provide 
good quality 
service 
Mission facilities 
charge for the 
medicines 
dispensed but 
the poor are 
exempted from 
paying 
   
GILSON et al 
1995 
Tanzania Quantitative 
analysis 
Yes Not 
specified 
Dispense 
medicines and 
medical 
supplies 
 
High stock 
levels of 
medicines 
and medical 
supplies in 
church 
dispensaries, 
no 
contraception 
services, Poor 
immunization 
services 
Church 
dispensaries 
provides quality 
services 
 
  Irregular 
vaccine 
supplies 
 Church 
dispensary 
understaffed. 
Training for 
staff annually 
GRIMAUD 
1998. . 
Ivory coast Case study Yes Yes Dispensing 
medicines 
Consultation 
fees, drug sales, 
reduced 
government 
and donor 
support 
Decrease in 
patients turn 
out due to 
cost 
Was known to 
provide 
affordable, 
rational and 
quality health 
care service 
High costs of 
medicines and 
other services 
 
Medicine 
shortages  
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AIDS ACTION 
1999 
Burkina Faso Report Yes Yes Medicine 
procurement 
and dispensing 
IPC (Initiative 
Privée et 
Communautaire 
de lutte contre 
le SIDA) fund 
the purchase of 
medicines 
ARVs and 
related 
medicines 
dispensed for 
free 
    
  
KAWASAKI et 
al 2002. 
Kenya and 
Uganda 
Qualitative 
and 
quantitative 
Yes  Not 
specified 
Procurement 
and supply of 
medicines to 
mission 
facilities, NGOs 
and the public 
sector 
JMS receives 
funding from 
international 
donors while 
JMS is self-
sustaining 
MEDS and 
JMS have 
good drug 
stock level 
and better 
access to 
medicines 
 
Cost of 
medicines from 
both 
organizations 
are higher than 
that of MSH 
price guide, JMS 
medicines cost 
13% higher than 
the price index, 
MEDS medicines 
is 1% higher 
MEDS is 
involved in 
quality 
assurance to 
meet the 
demands of 
their 
customers.  
 
 MEDS work 
closely with 
EPN in 
training of 
pharmacy 
professionals 
ANDREWS, E. 
2004. 
Ghana  Interviews Yes Not 
specified 
Medicines 
procurement 
and dispensing 
 
Medicines 
dispensed for 
free to the 
poor at 
mission 
facilities 
while the rest 
pay 
 
Medicines and 
related 
commodities 
cost more at 
mission facilities 
compared to 
public sector 
mission sector 
adheres to 
prescribing 
regulation 
 
  
BANDA et al 
2006 
Multi-country  Questionnaire Yes Yes  Supply of 
medicines in 
rural and 
remote areas 
in Africa  
Faith-based 
drug supply 
organization 
involved in 
funding for 
most of the 
African 
population 
Improved 
access 
because of 
medicines are 
dispensed at 
affordable 
cost or at no 
cost.  
Patients trust 
faith-based drug 
supply 
organizations for 
quality medicines 
at affordable 
costs. 
Cost of 
medicines are 
affordable 
Weakness in 
quality 
assurance of 
medicines and 
compliance 
with drug 
regulatory 
body 
 
  
LUM et al 
2007. 
 Nigeria Retrospective 
study  
Yes Yes Supply of ART 
and related 
medicines, 
Adherence 
monitoring 
through home 
care visits 
Medicines 
supply funded 
by PEPFAR and 
private donors 
Supply of 
medicines 
and other 
services at no 
cost  
 
Medicines 
supply, and 
other services 
are free of 
charge. 
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BALLOU-
AARES et al 
2008. 
Ghana and 
Zambia  
 
Yes  Yes Dispensing of 
medicines to 
the poor in 
remote and 
rural areas 
 Inadequate 
resources and 
delay in 
payments from 
NHI. 
Medicines 
and related 
commodities 
accessible to 
the poor and 
those in rural 
and remote 
areas. 
 
Faith-based 
facilities supply 
medicines at no 
cost in Zambia 
  
  
CARLUCCI et al 
2008. 
 Zambia Interview Yes  Yes  Dispensing of 
ART to 
adherent HIV 
positive 
patients in 
rural Zambia 
 Receive ART 
from 
government 
and AIDS Relief, 
procured 
medicines from 
government 
medical stores 
and private 
sector. 
ART supplied 
to adherent 
patients, 
serve almost 
half of the 
HIV positive 
population in 
the 
catchment 
area.   
 
ART and related 
medicines are 
supplied at no 
cost 
  
  
NJOZING et al 
2010. 
Cameroon   Retrospective 
cohort study  
Not 
specified 
Not 
specified 
Supply of ART 
and 
Cotrimoxazole 
preventive 
therapy to HIV 
positive TB 
patients 
 
 Almost half 
of HIV 
positive TB 
patients were 
enrolled on 
ART and co-
trimoxazole 
preventive 
therapy at 
faith-based 
facilities. 
    
  
ROOKES, P. J. 
2010 
Malawi  Qualitative  Yes Not 
specified 
Dispensing 
medicines and 
related 
commodities   
Purchase 
medicines from 
the private-for-
profit sector 
because of the 
from 
government, 
sale of 
medicines 
Faith-based 
facilities in 
Malawi 
charge for 
medicines to 
prevent over 
population 
 
Faith-based 
facilities in 
Malawi do not 
charge the poor 
patients 
identified by the 
staff do not pay 
for medicines 
 
Irregularity 
of medicine 
supply 
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MCCABE et al 
2011. 
Ghana, Malawi 
and Mali  
Report Yes  Not 
specified  
Maintaining 
good medicine 
stock level and 
dispensing  
Payment in full 
or copayment 
by health 
insurance   
schemes in 
Malawi, CHAM 
supported by 
government, 
international 
donations and 
medicines sales 
Medicines 
and related 
commodities 
supplied at 
no minimal at 
mission 
facilities 
  
.  
  
EP NETWORK 
2016. 
Africa   Report Yes Yes  Capacity 
building, 
advocacy and 
awareness 
raising 
pharmaceuticals 
procured 
through bulk 
purchasing 
Improving 
access to 
family 
planning 
commodity 
through EPN 
stakeholder 
engagement 
and 
empowering 
pharmacy 
personnel 
 
Supply 
medicines and 
related 
commodities to 
faith-based and 
public facilities 
at affordable 
cost. 
Non-
adherence to 
treatment 
guidelines, 
support quality 
assurance 
testing. 
 
Training of 
pharmacy 
staff. 
KAREEN 
SHAWA-
DURAND 2017 
Africa  Report  Not 
specified  
Not 
specified 
Training of 
pharmacy 
personnel  
 
Improved 
access to 
medicines 
due to 
increase 
trained 
personnel 
    
EPN support 
training of 
pharmacy 
personnel  
KHULUZAFELIX 
et al 2017 
Malawi  Drug 
availability 
and price 
recorded 
Yes  yes Medicines 
procurement 
and dispensing 
International 
donors fund 
purchase of 
malaria 
medicines, 
medicines sales 
at CHAM facility 
High stock of 
medicines at 
CHAM 
facilities 
compared to 
government, 
Medicines 
from the 
government 
and donors 
dispensed 
free 
All the medicines 
Passed quality 
 assurance testing 
Drug cost more 
at CHAM facility 
than that at 
private for-profit 
sector 
All medicines 
at the CHAM 
facilities 
passed quality 
assurance test 
Low stock of 
antibiotics 
and stock 
out of 
quinine 
injection in 
many CHAM 
facilities. 
 
KHULUZAFELIX 
et al 2017 
Malawi  Samples 
collection 
survey 
Yes  Not 
specified 
Quality 
assurance of 
medicines at 
facilities 
    
All the 
medicines at 
CHAM facilities 
passed quality 
assurance test 
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KIBIRA et al 
2017. 
Uganda  Survey  Not 
specified 
Not 
specified 
 Stock level 
and cost of 
maternal and 
reproductive 
health at 
mission 
facilities 
Medicines are 
expensive in 
Uganda 
compared to 
international 
reference price. 
Good stock of 
Maternal 
reproductive 
health 
medicines at 
mission 
facilities 
compared to 
private-for-
profit 
facilities 
 
Medicines 
unaffordable 
due to high 
prices. 
Medicines 
cheaper at 
mission facilities 
compared to 
private for 
profit.   
 
High stock 
out of 
medicines 
at mission 
facilities 
compared 
to 
government 
facilities. 
 
PETERSEN et 
al. 2017. 
LMIC/ Multi-
County study 
Laboratory 
test 
Yes   Yes  Use of faith-
based drug 
supply 
organizations 
to test the 
quality of 
essential 
medicines in 
the 
pharmaceutical 
market. 
Process funded 
by international 
donors 
 
Medicine from 
 Europe found  
to be of poor 
 quality compared  
to those from  
Sub-Saharan 
 Africa 
 
Private 
pharmaceutical 
sector in 
Cameroon, 
DRC and 
Nigeria had 
Falsified and 
substandard 
medicines, 
Antimalarial 
medicines 
found to be 
the most 
falsified and 
substandard 
drug 
 
Training of 
pharmacy 
personnel at 
the faith-
based drug 
organizations 
were trained 
on how the 
instrument 
works. 
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Appendix B: Search terms 
Main term Related terms 
Pharma* Cold chain OR Drug distribution OR Drugs distribution OR Drug supply OR Drugs supply OR ART OR 
Medicine OR Medicine price OR Drug Procurement OR Dispensary OR Drug system OR 
Pharmaceutical Services OR pharmacy services OR pharmaceutical supply OR medicine OR 
procurement OR medicines procurement OR medicine supply OR medicines supply  
Non-state provider NSP OR Non-state providers OR Non-profit OR Not-for-profit OR non-profit OR 
NPO OR Private-not-for-profit OR PNFP OR Non-governmental organization OR NGO OR ngo OR  
faith community OR faith communities OR Charities OR Faith-based OR Faith OR Religious OR 
Religion OR mission OR church OR JMS OR Joint Medical Stores OR CHANPHARM OR Christian 
Health Association of Nigeria OR MEDS OR Mission for Essential Drug Supplies ORCDC OR Catholic 
Drug Centre OR MEMS OR Mission for Essential Medical Supplies OR CSSC OR Catholic Social 
Services Commission OR CBC OR Cameroon Baptist Convention OR CHAM OR Christian Health 
Association of Malawi OR CHAZ OR Christian Health Association of Zambia OR AMFA OR affordable 
medicines for Africa OR BUFMAR OR Bureau des Formations Médicales Agréées du Rwanda OR 
OSEELC OR Oeuvre de Santé de lʹÉglise Évangélique Luthérienne au Cameroun   
EEC OR Église Évangélique du Cameroun OR CAP/EPC OR 
Centrale dʹApprovisionnement en Médicaments de lʹÉglise OR OCASC OR 
Organization catholique pour la Santé au Cameroun 
Region Africa OR African OR Algeria OR Angola OR Benin OR Botswana OR “Burkina Faso” OR Burundi OR 
Cameroon OR “Cape Verde” OR “Cabo Verde” OR “Central African Republic” OR Chad OR Comoros 
OR Comores OR Comoro OR Congo OR “Congo-Brazzaville” OR “Congo Republic” OR “Republic of 
the Congo” “Côte d'Ivoire” OR “Democratic Republic of the Congo” OR “DR Congo” OR DRC OR 
“Congo-Kinshasa” OR Djibouti OR Egypt OR  “Equatorial Guinea” OR Eritrea OR Eswatini OR 
Ethiopia OR Gabon OR Gambia OR “The Gambia” OR Ghana OR Guinea OR Guinea-Bissau OR Kenya 
OR Lesotho OR Liberia OR Libya OR Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius 
OR Morocco  OR Mozambique OR Namibia OR Niger OR Nigeria OR Rwanda OR “Sao Tome and 
Principe” OR “São Tomé and Príncipe” OR Senegal OR Seychelles OR “Sierra Leone” OR Somalia OR 
“South Africa” OR “South Sudan” OR Sudan OR Swaziland OR Togo OR Tunisia OR Uganda OR 
“United Republic of Tanzania” OR Tanzania OR Zambia OR Zimbabwe 
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Appendix C: Search strategy  
Database  Date 
searched  
Terms  Results 
PubMed 07/08/ 2018 Search ((("Cold chain" OR "Drug distribution"[Title/Abstract] OR "Drugs 
distribution"[Title/Abstract] OR "Drug supply"[Title/Abstract] OR "Drugs 
supply"[Title/Abstract] OR "ART"[Title/Abstract] OR Medicine[Title/Abstract] OR 
"Medicine price"[Title/Abstract] OR "Drug Procurement"[Title/Abstract] OR 
Dispensary[Title/Abstract] OR "Drug system"[Title/Abstract] OR "Pharmaceutical 
Services"[Title/Abstract] OR "pharmacy services"[Title/Abstract] OR "pharmaceutical 
supply"[Title/Abstract] OR "medicine procurement"[Title/Abstract] OR "medicines 
procurement"[Title/Abstract] OR "medicine supply"[Title/Abstract] OR "medicines 
supply"[Title/Abstract])) AND (faith[Title/Abstract] OR charit*[Title/Abstract] OR 
relig*[Title/Abstract] OR mission*[Title/Abstract] OR church[Title/Abstract])) AND (Africa 
OR African OR Algeria OR Angola OR Benin OR Botswana OR "Burkina Faso" OR Burundi 
OR Cameroon OR "Cape Verde" OR "Cabo Verde" OR "Central African Republic" OR Chad 
OR Comoros OR Comores OR Comoro OR Congo OR "Congo-Brazzaville" OR "Congo 
Republic" OR "Republic of the Congo" OR "Cote d'Ivoire" OR "Democratic Republic of the 
Congo" OR "DR Congo" OR DRC OR "Congo-Kinshasa" OR Djibouti OR Egypt OR 
"Equatorial Guinea" OR Eritrea OR Eswatini OR Ethiopia OR Gabon OR Gambia OR "The 
Gambia" OR Ghana OR Guinea OR Guinea-Bissau OR Kenya OR Lesotho OR Liberia OR 
Libya OR Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius OR Morocco OR 
Mozambique OR Namibia OR Niger OR Nigeria OR Rwanda OR "Sao Tome and Principe" 
OR "Sao Tome and Principe" OR Senegal OR Seychelles OR "Sierra Leone" OR Somalia OR 
"South Africa" OR "South Sudan" OR Sudan OR Swaziland OR Togo OR Tunisia OR Uganda 
OR "United Republic of Tanzania" OR Tanzania OR Zambia OR Zimbabwe) 
657 
EBSCOhost 
Africa-wide 
Information 
426  
CINAHL 22  
 
08/08/2018 TI ( "Cold chain" OR" Drug distribution" OR "Drugs distribution" OR "Drug supply" OR 
"Drugs supply" OR "ART" OR Medicine OR "Medicine price" OR "Drug Procurement" OR 
Dispensary OR "Drug system" OR "Pharmaceutical Services" OR "pharmacy services" OR 
"pharmaceutical supply" OR "medicine procurement" OR "medicines procurement" OR 
"medicine supply" OR "medicines supply" ) AND AB ( faith OR charit* OR relig* OR 
mission* OR church ) AND TX ( Africa OR African OR Algeria OR Angola OR Benin OR 
Botswana OR “Burkina Faso” OR Burundi OR Cameroon OR “Cape Verde” OR “Cabo 
Verde” OR “Central African Republic” OR Chad OR Comoros OR Comores OR Comoro OR 
Congo OR “Congo-Brazzaville” OR “Congo Republic” OR “Republic of the Congo” OR “Côte 
d'Ivoire” OR “Democratic Republic of the Congo” OR “DR Congo” OR DRC OR “Congo-
Kinshasa” OR Djibouti OR Egypt OR “Equatorial Guinea” OR Eritrea OR Eswatini OR 
Ethiopia OR Gabon OR Gambia OR “The Gambia” OR Ghana OR Guinea OR Guinea-Bissau 
OR Kenya OR Lesotho OR Liberia OR Libya OR Madagascar OR Malawi OR Mali OR 
Mauritania OR Mauritius OR Morocco OR Mozambique OR Namibia OR Niger OR Nigeria 
OR Rwanda OR “Sao Tome and Principe” OR “São Tomé and Príncipe” OR Senegal OR 
Seychelles OR “Sierra Leone” OR Somalia OR “South Africa” OR “South Sudan” OR Sudan 
OR Swaziland OR Togo OR Tunisia OR Uganda OR “United Republic of Tanzania” OR 
Tanzania OR Zambia OR Zimbabwe ) 
448 
  
Web of 
Science 
09/08/2018 TITLE: ("Cold chain" OR" Drug distribution" OR "Drugs distribution" OR "Drug supply" OR 
"Drugs supply" OR "ART" OR Medicine OR "Medicine price" OR "Drug Procurement" OR 
Dispensary OR "Drug system" OR "Pharmaceutical Services" OR "pharmacy services" OR 
"pharmaceutical supply" OR "medicine procurement" OR "medicines procurement" OR 
"medicine supply" OR "medicines supply") AND TOPIC: (faith OR charit* OR relig* OR 
mission* OR church) AND TOPIC: (Africa OR African OR Algeria OR Angola OR Benin OR 
Botswana OR Burkina Faso OR Burundi OR Cameroon OR Cape Verde OR Cabo Verde OR 
Central African Republic OR Chad OR Comoros OR Comores OR Comoro OR Congo OR 
Congo-Brazzaville OR Congo Republic OR Republic of the Congo OR Côte d'Ivoire OR 
Democratic Republic of the Congo OR DR Congo OR DRC OR Congo-Kinshasa OR Djibouti 
OR Egypt OR Equatorial Guinea OR Eritrea OR Eswatini OR Ethiopia OR Gabon OR Gambia 
OR The Gambia OR Ghana OR Guinea OR Guinea-Bissau OR Kenya OR Lesotho OR Liberia 
OR Libya OR Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius OR Morocco 
OR Mozambique OR Namibia OR Niger OR Nigeria OR Rwanda OR Sao Tome and Principe 
OR São Tomé and Príncipe OR Senegal OR Seychelles OR Sierra Leone OR Somalia OR 
South Africa OR South Sudan OR Sudan OR Swaziland OR Togo OR Tunisia OR Uganda OR 
United Republic of Tanzania OR Tanzania OR Zambia OR Zimbabwe) 
446 
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Appendix D: Bibliography of documents identified in the systematic review 
AIDS action. 1999. Making drugs accessible. AIDS Action, 5. 
Andrews E. 2004. Medicine prices in Ghana: A comparative study of public, private and mission sector medicine prices. 
Geneva: Health Action International (HAI). Available at: 
http://apps.who.int/medicinedocs/documents/s18074en/s18074en.pdf. 
Asamoah D, Annan J, Nyarko S. 2012. AHP approach for supplier evaluation and selection in a pharmaceutical 
manufacturing firm in Ghana. International Journal of Business and Management, 7: 49. 
Asenso-Okyere WK. 1995. Financing health care in Ghana. World Health Forum, 16: 86-91. 
Ballou-Aares D, Freitas A, Kopczak LR, et al. 2008. Private sector role in health supply chains: Review of the role and 
potential for private sector engagement in developing country health supply chains. Available at: 
http://apps.who.int/medicinedocs/documents/s16323e/s16323e.pdf. 
Banda M, Ombaka E, Everard M. 2006. Multi-country study of medicine supply and distribution activities of faith-based 
organizations in sub-Saharan African countries. Available at: Carlucci JG, Kamanga A, Sheneberger R, et al. 2008. 
Predictors of adherence to antiretroviral therapy in rural Zambia. Journal of Acquired Immune Deficiency 
Syndrome, 47: 615-622. 
Ecumenical Pharmaceutical Network. 2016. Ecumenical Pharmaceutical Network Annual Report. Available at 
:http://www.epnetwork.org  
Gilson L, Magomi M, Mkangaa E. 1995. The structural quality of Tanzanian primary health facilities. Bulletin of the 
World Health Organization, 73: 105-114. 
Grimaud O. 1998. The provision of private charitable hospital care in west Africa – A case study. Journal of Public Health 
Medicine, 20: 125-128. 
Kareen Shawa-Duran. 2017. Until every church health facility has qualified pharmaceutical staff. Avilable at: 
http://www.medicusmundi.org/contributions/reports/2018/until-every-church-health-facility-has-qualified-
pharmaceutical-staff/mmi-annual-report-2017-epn.pdf.  
Kawasaki E, Patten JP. 2002. Drug supply systems of missionary organizations. Identifying factors affecting expansion 
and efficiency: Case studies from Uganda and Kenya. Geneva, Switzerland: World Health Organization. Available 
at: http://apps.who.int/medicinedocs/documents/s21432en/s21432en.pdf. 
Khuluza F, Kigera S, Heide L. 2017. Low prevalence of substandard and falsified antimalarial and antibiotic medicines in 
public and faith-based health facilities of southern Malawi. American Journal of Tropical Medicine and Hygiene, 
96: 1124-1135. 
KhuluzaFelix, Heide L. 2017. Availability and affordability of antimalarial and antibiotic medicines in Malawi. PloS One, 
12: e0175399. 
Kibira D, Kitutu FE, Merrett GB, Mantel-Teeuwisse AK. 2017. Availability, prices and affordability of UN Commission's 
lifesaving medicines for reproductive and maternal health in Uganda. Journal of Pharmaceutical Policy and 
Practice, 10: 35. 
Lum H, Isichei C, Isichei-Wakili M, Redfield R. 2007. Expansion of HIV-1 screening and anti-retroviral treatment 
programs in a resource-poor setting: results from a faith-based organization in Jos, Plateau State, Nigeria. African 
Health Sciences, 7: 93-100. 
McCabe A, Seiter A, Diack A, et al. 2011. Private sector pharmaceutical supply and distribution channels in Africa: a 
focus on Ghana, Malawi and Mali. Available at: 
http://documents.worldbank.org/curated/en/745621468270302773/Private-sector-pharmaceutical-supply-and-
distribution-chains-Ghana-Mali-and-Malawi. 
Njozing NB, Miguel SS, Tih PM, Hurtig AK. 2010. Assessing the accessibility of HIV care packages among tuberculosis 
patients in the Northwest Region, Cameroon. BMC Public Health, 10: 129. 
Petersen A, Held N, Heide L, Difam EPNMSG. 2017. Surveillance for falsified and substandard medicines in Africa and 
Asia by local organizations using the low-cost GPHF Minilab. PLoS One, 12: e0184165. 
Rookes PJ. 2010. Commitment, conscience or compromise: The changing financial basis and evolving role of Christian 
health services in developing countries. University of Birmingham. Available at : 
http://etheses.bham.ac.uk/829/1/Rookes10PhD_A1a.pdf. 
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Appendix E: Instructions for authors: Health Policy and Planning  
Health Policy and Planning improves the design, implementation and evaluation of health policies in low- and 
middle-income countries through providing a forum for publishing high quality research and original ideas, for an 
audience of policy and public health researchers and practitioners. HPP is published 10 times a year. 
 
HPP has a double-blinded peer-review policy. All types of papers are peer reviewed and all article abstracts from each 
issue are translated into French, Spanish and Chinese. Before you submit please make sure you have followed all the 
relevant instructions. A checklist for authors is available here. 
• Guidance  
i. Improving chances of publication  
ii. Manuscript format and style for all articles  
• Types of papers  
• Submission process  
Guidance 
Improving chances of publication 
As well as the high overall quality required for publication in an international journal, authors should take into 
consideration:  
• Addressing HPP's readership: national and international policy makers, practitioners, academics and general 
readers with a particular interest in health policy issues and debates.  
• Manuscripts that fail to set out the international debates to which the paper contributes, and to draw out 
policy lessons and conclusions, are more likely to be rejected, returned to the authors for redrafting prior to 
being reviewed, or undergo a slower acceptance process.  
• Economists should note that papers accepted for publication in HPP will consider the broad policy implications 
of an economic analysis rather than focusing primarily on the methodological or theoretical aspects of the 
study.  
• Public health specialists writing about a specific health problem or service should discuss the relevance of the 
analysis for the broader health system. Those submitting health policy analyses should draw on relevant 
bodies of theory in their analysis, or justify why they have not, rather than only presenting a narrative based 
on empirical data.  
• Primarily focus on one or more low- or middle-income countries.  
The editors cannot enter into correspondence about papers considered unsuitable for publication and their decision is 
final. Neither the editors nor the publishers accept responsibility for the views of authors expressed in their 
contributions. The editors reserve the right to make amendments to the papers submitted although, whenever 
possible, they will seek the authors' consent to any significant changes made. The manuscript will not be returned to 
authors following submission unless specifically requested.  
Should you require any assistance in submitting your article or have any queries, please do not hesitate to contact the 
editorial office at hpp.editorialoffice@oup.com. 
 
Manuscript format and style for all articles 
Only articles in English are considered for publication. 
Prepare your manuscript, including tables, using a word processing program and save it as a .doc, .rtf or .ps file. Use a 
minimum font size of 11, double-spaced and paginated throughout including references and tables, with margins of at 
least 2.5 cm. The text should be left justified and not hyphenated.  
The title page should contain:  
• Title - please keep as concise as possible and ensure it reflects the subject matter  
• Corresponding author's name, address, telephone/fax numbers and e-mail address  
• Each author's affiliation and qualifications  
• Keywords and an abbreviated running title  
• 2-4 Key Messages, detailing concisely the main points made in the paper  
• Acknowledgements  
• A word count of the full article  
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In the acknowledgements, all sources of funding for research must be explicitly stated, including grant numbers if 
appropriate. Other financial and material support, specifying the nature of the support, should be acknowledged as 
well.  
Figures should be designed using a well-known software package for standard personal computers. If a figure has been 
published earlier, acknowledge the original source and submit written permission from the copyright holder to 
reproduce the material. Colour figures are permitted but authors will be required to pay the cost of reproduction. 
Please be aware that the requirements for online submission and for reproduction in the journal are different: (i) for 
online submission and peer review, please upload your figures separately as low-resolution images (.jpg, .tif, .gif or. 
eps); (ii) for reproduction in the journal, you will be required after acceptance to supply high-resolution .tif files. 
Minimum resolutions are 300 d.p.i. for colour or tone images, and 600 d.p.i. for line drawings. We advise that you 
create your high-resolution images first as these can be easily converted into low-resolution images for online 
submission.    
Figures will not be relettered by the publisher. The journal reserves the right to reduce the size of illustrative material. 
Any photomicrographs, electron micrographs or radiographs must be of high quality. Wherever possible, photographs 
should fit within the print area or within a column width. Photomicrographs should provide details of staining 
technique and a scale bar. Patients shown in photographs should have their identity concealed or should have given 
their written consent to publication. When creating figures, please make sure any embedded text is large enough to 
read. Many figures contain miniscule characters such as numbers on a chart or graph. If these characters are not easily 
readable, they will most likely be illegible in the final version.  
Certain image formats such as .jpg and .gif do not have high resolutions, so you may elect to save your figures and 
insert them as .tif instead. 
For useful information on preparing your figures for publication, go to http://cpc.cadmus.com/da . 
All measures should be reported in SI units, followed (where necessary) by the traditional units in parentheses. There 
are two exceptions: blood pressure should be expressed in mmHg and haemoglobin in g/dl. For general guidance on 
the International System of Units, and some useful conversion factors, see 'The SI for the Health Professions' (WHO 
1977). 
Manuscript file must include text body. Title Page, Figures and Tables should be uploaded separately.  
Manuscript Preparation  
Page 1: Title Page – as above.  
Page 2: Abstract. The abstract should be prepared in one paragraph, no headings are required. It should describe the 
purpose, materials and methods, results, and conclusion in a single paragraph no longer than 300 words without line 
feeds.  
 
Page 3: Introduction. The Introduction should state the purpose of the investigation and give a short review of the 
pertinent literature and be followed by:  
 
Materials and methods. The Materials and methods section should follow the Introduction and should provide enough 
information to permit repetition of the experimental work. For particular chemicals or equipment, the name and 
location of the supplier should be given in parentheses.  
 
Results. The Results section should describe the outcome of the study. Data should be presented as concisely as 
possible, if appropriate in the form of tables or figures, although very large tables should be avoided.  
Discussion. The Discussion should be an interpretation of the results and their significance with reference to work by 
other authors. 
Abbreviations. Non-standard abbreviations should be defined at the first occurrence and introduced only where 
multiple use is made. Authors should not use abbreviations in headings. 
All measures should be reported in SI units, followed (where necessary) by the traditional units in parentheses. There 
are two exceptions: blood pressure should be expressed in mmHg and haemoglobin in g/dl. For general guidance on 
the International System of Units, and some useful conversion factors, see 'The SI for the Health Professions' (WHO 
1977). 
References. References must follow the Harvard system and must be cited as follows:  
 
Baker and Watts (1993) found...  
 
In an earlier study (Baker and Watts 1993), it...  
 
Where works by more than two authors are cited, only the first author is named followed by 'et al.' and the year. The 
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reference list must be typed double-spaced in alphabetical order and include the full title of both paper (or chapter) 
and journal (or book), thus:  
 
Baker S, Watts P. 1993. Paper/chapter title in normal script. Journal/book title in italics Volume number in bold: page 
numbers.  
 
Baker S, Watts P. 1993. Chapter title in normal script. In: Smith B (ed). Book title in italics. 2nd edn. Place of 
publication: Publisher's name, page numbers.  
Tables All tables should be on separate pages and accompanied by a title - and footnotes where necessary. The tables 
should be numbered consecutively using Arabic numerals. Units in which results are expressed should be given in 
parentheses at the top of each column and not repeated in each line of the table. Ditto signs are not used. Avoid 
overcrowding the tables and the excessive use of words. The format of tables should be in keeping with that normally 
used by the journal; in particular, vertical lines, coloured text and shading should not be used. Please be certain that the 
data given in tables are correct. Tables should be provided as Word or Excel files. 
Types of papers  
Health Policy and Planning welcomes submissions of the following article types: 
• Original research  
• Review articles  
• Methodological musings  
• Innovation and practice reports  
• Commentaries  
• 'How to do (or not to do)...' [for example, see Hutton & Baltussen, HPP, 20(4): 252-9] and  
• '10 best resources' [for example, see David & Haberlen, HPP, 20(4): 260-3].  
ORIGINAL RESEARCH  
Manuscripts should preferably be a maximum of 6,000 words, excluding tables and figures/diagrams. 
The manuscript will generally follow through sections: Title page (as above), Abstract (no more than 300 words), 
Introduction, Methods, Results, Discussion, Conclusion, Acknowledgements, References. However, it may be 
appropriate to combine the results and discussion sections in some papers. Tables and Figures should not be placed 
within the text, rather provided in separate file/s. 
For the reporting of statistical analyses please consider the following additional points:  
• Focus the statistical analysis at the research question.  
• Provide information about participation and missing data.  
• As much as possible, describe results using meaningful phrases (e.g., do not say "beta" or "regression 
coefficient", but "mean change in Y per unit of X"). Provide 95% confidence intervals for estimates.  
• Report the proportions as N (%), not just %.  
• Report P values with 2 digits after the decimal, 3 if <0.01 or near 0.05 (e.g., 0.54, 0.03, 0.007, <0.001, 0.048). 
Do not report P values greater than 0.05 as "NS".  
• Always include a leading zero before the decimal point (e.g., 0.32 not .32).  
• Do not report tests statistics (such as chi-2, T, F, etc.)."  
For acknowledgements, figures and measures see above. 
 
REVIEW ARTICLES  
Manuscripts should preferably be a maximum of 10,000 words, excluding tables, figures/diagrams and references. 
Reviews may be invited. They generally address recent advances in health policy, health systems and implementation. 
Systematic reviews are particularly welcomed but may not be appropriate for every topic. If authors are submitting a 
review article that is not a systematic review then the paper should explain why a systematic review was not 
feasible/desirable, and the review methods should be described in a way that is as clear and as replicable as possible.  
The manuscript will generally follow through sections: Abstract (no more than 300 words), Introduction, Methods, 
Results, Discussion, Conclusion, References. However, it may be appropriate to combine the results and discussion 
sections in some papers. Tables and Figures should not be placed within the text, rather provided in separate file/s.  
Checklists have been developed for a number of study designs, including randomized controlled trials (CONSORT), 
systematic reviews (PRISMA), observational studies (STROBE), diagnostic accuracy studies (STARD) and qualitative 
studies (COREQ, RATS). We recommend authors refer to the EQUATOR Network website (http://www.equator-
network.org) for further information on the available reporting guidelines for health research, and the MIBBI Portal for 
prescriptive checklists for reporting biological and biomedical research where applicable. Authors are requested to 
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make use of these when drafting their manuscript and peer reviewers will also be asked to refer to these checklists 
when evaluating these studies.  
 
COMMENTARIES  
Short commentaries on topical issues in health systems are welcomed - please email the editorial office prior to 
submission. Most such commentaries are commissioned by the editors, but the journal will also consider unsolicited 
submissions. Commentaries should of broad interest to readers of Health Policy and Planning, and while they are not 
research papers, they should be well substantiated. Manuscripts should preferably be a maximum of 1,200 words, 
excluding tables, figures/diagrams and references. 
The manuscript will generally contain a short set of key take-home messages. Tables and Figures should not be placed 
within the text, rather provided in separate file/s. 
HOW TO DO...OR NOT TO DO  
This series is meant to explain how to use a particular research or analytical method (e.g. social network analysis, 
discrete choice experiment etc.). The research or analytical methods discussed should be well accepted and clearly 
defined: this category of paper is not meant to address methodological debates but rather to help disseminate and 
promote the use of well-accepted methodologies.  
 
Manuscripts should preferably be a maximum of 3,000 words excluding tables, figures/diagrams and references. 
• The sections must be arranged as follows: i) Title page (as above), ii) Abstract, iii) Introduction, iv) Body of the 
paper, and v) References. Main sections should be coordinated by the author and inserted between 
Introduction and Reference sessions. Please contact our office before submitting a manuscript in this category.  
Tables and Figures should not be placed within the text, rather provided in separate file/s.  
 
10 BEST RESOURCES  
This 10 best is a series of articles that identify and outline the 10 most useful resources from a range of sources to help 
facilitate a better understanding of a particular issue in global health. 
We often commission these articles but we also hear unsolicited suggestions.  
For acknowledgements, figures and measures see above. 
METHODOLOGICAL MUSINGS  
This series is meant to address methodological issues in health policy and systems research, where there is currently a 
lack of clarity about accepted research methods. This series is intended to support the development of the health policy 
and systems research field, through supporting methodological discussion.  
 
Manuscripts should preferably be a maximum of 3,000 words, excluding tables, figures/diagrams and references.  
• The sections must be arranged as follows: i) Title page (as above), ii) Abstract, iii) Introduction, iv) Body of the 
paper, and v) References. Main sections should be coordinated by the author, and inserted between 
Introduction and Reference sessions. Please contact our office before submitting a manuscript in this category.  
• For acknowledgements, figures and measures see above.  
INNOVATION AND PRACTICE REPORTS  
These short reports are narratives from the perspective of health managers operating at the national or sub-national 
level which focus on innovative approaches to strengthen health systems. Papers should highlight the practical 
experience of health managers or practitioners involved in taking action to strengthen health systems through 
innovative activities and new practices. The new activities and practices should preferably have been implemented for a 
sufficiently long time to allow authors to demonstrate the potential for sustained improvement or change in the health 
system. Examples might include practices to build capacity, develop new partnerships or restructure relationships 
within health systems. Papers should identify 2-4 key messages or lessons for consideration in other settings. We will 
not consider clinical and pharmaceutical innovations and practices. Manuscripts should be a maximum of 2,000 words.  
The manuscript will generally follow through sections: Key Messages, Abstract (no more than 300 words), Introduction, 
Methods, Results, Discussion, Conclusion, References. However, it may be appropriate to combine the results and 
discussion sections in some papers. Tables and Figures should not be placed within the text, rather provided in separate 
file/s. In the main body of the paper, sub-headings may be useful to signal key elements of the experience reported. 
Reports must be led by local practitioners, managers or policy-makers.  
Submission process  
• Pre-submission language editing  
• Authorship  
• Originality  
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• Online submission  
PRE-SUBMISSION LANGUAGE EDITING 
HPP asks all authors to ensure that their papers are written in as high a standard of English as possible before 
submission to the journal. If your first language is not English, to ensure that the academic content of your paper is fully 
understood by journal editors and reviewers, you may want to consider using a language editing service. Language 
editing does not guarantee that your manuscript will be accepted for publication. For further information on this 
service, please click here. Several specialist language editing companies offer similar services and you can also use any 
of these. Authors are liable for all costs associated with such services. If your first language is not English, to ensure that 
the academic content of your paper is fully understood by journal editors and reviewers is optional. Language editing 
does not guarantee that your manuscript will be accepted for publication. For further information on this service, 
please click here. Several specialist language editing companies offer similar services and you can also use any of these. 
Authors are liable for all costs associated with such services.  
AUTHORSHIP 
All persons designated as authors should qualify for authorship. The order of authorship should be a joint decision of 
the co-authors. Each author should have participated sufficiently in the work to take public responsibility for the 
content. Authorship credit should be based on substantial contribution to conception and design, execution, or analysis 
and interpretation of data. All authors should be involved in drafting the article or revising it critically for important 
intellectual content, must have read and approved the final version of the manuscript and approve of its submission to 
this journal. An email confirming submission of a manuscript is sent to all authors. Any change in authorship following 
initial submission would have to be agreed by all authors as would any change in the order of authors.  
ORIGINALITY 
Manuscripts containing original material are accepted for consideration with the understanding that neither the article 
nor any part of its essential substance, tables, or figures has been or will be published or submitted for publication 
elsewhere. This restriction does not apply to abstracts or short press reports published in connection with scientific 
meetings. Copies of any closely related manuscripts should be submitted along with the manuscript that is to be 
considered by HPP. HPP discourages the submission of more than one article dealing with related aspects of the same 
study. . For further information on the prior publication policy see 
https://academic.oup.com/heapol/pages/Prior_Publication.  
During the online submission procedure, authors are asked to provide: 
• information on prior or duplicate publication or submission elsewhere of any part of the work;  
• a statement of financial or other relationships that might lead to a conflict of interest or a statement that the 
authors do not have any conflict of interest;  
• a statement that the manuscript has been read and approved by all authors (see also section on authorship);  
• name, address, telephone and fax number of the corresponding author who is responsible for negotiations 
concerning the manuscript;  
• copies of any permissions to reproduce already published material, or to use illustrations or report sensitive 
personal information about identifiable persons.  
All papers submitted to HPP are checked by the editorial office for conformance to author and other instructions all 
specified below. Non-conforming manuscripts will be returned to authors. 
If authors are unsure about the originality of their manuscript or any part of it, they should contact the editorial office 
at hpp.editorialoffice@oup.com. 
ONLINE SUBMISSION 
Prior to submission please carefully read instructions on each type of paper and closely follow instructions on word 
count, abstract, tables and figures and references. This will ensure that the review and publication of your paper is as 
efficient and quick as possible. The Editorial Office reserve the right to return manuscripts that are not in accordance 
with these instructions.  
 
All material to be considered for publication in Health Policy and Planning should be submitted in electronic form via 
the journal's online submission system. Once you have prepared your manuscript according to the instructions below, 
instructions on how to submit your manuscript online can be found by clicking here.  
CONFLICT OF INTEREST 
Authors must declare any conflicts of interest during the online submissions process. The lead author is responsible for 
confirming with the co-authors whether they also have any conflicts to declare. 
ETHICAL APPROVAL  
A requirement of publication is that research involving human subjects was conducted with the ethical approval of the 
appropriate bodies in the country where the research was conducted and of the ethical approval committees of 
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affiliated research institutions elsewhere. A clear statement to this effect must be made in any submitted manuscript 
presenting such research, specifying that the free and informed consent of the subjects was obtained.  
FUNDING 
The following rules should be followed: 
• The sentence should begin: ‘This work was supported by …’  
• The full official funding agency name should be given, i.e. ‘the National Cancer Institute at the National 
Institutes of Health’ or simply 'National Institutes of Health' not ‘NCI' (one of the 27 subinstitutions) or 'NCI at 
NIH’ - see the full RIN-approved list of UK funding agencies for details  
• Grant numbers should be complete and accurate and provided in brackets as follows: ‘[grant number ABX 
CDXXXXXX]’  
• Multiple grant numbers should be separated by a comma as follows: ‘[grant numbers ABX CDXXXXXX, EFX 
GHXXXXXX]’  
• Agencies should be separated by a semi-colon (plus ‘and’ before the last funding agency)  
• Where individuals need to be specified for certain sources of funding the following text should be added after 
the relevant agency or grant number 'to [author initials]'.  
An example is given here: ‘This work was supported by the National Institutes of Health [P50 CA098252 and CA118790 
to R.B.S.R.] and the Alcohol & Education Research Council [HFY GR667789]. 
Oxford Journals will deposit all NIH-funded articles in PubMed Central. See Author self-archiving policy for details. 
Authors must ensure that manuscripts are clearly indicated as NIH-funded using the guidelines above.  
PERMISSIONS  
Authors are reminded that it is their responsibility to comply with copyright laws. It is essential to ensure that no parts 
of the submission have or are due to appear in other publications without prior permission from the copyright holder 
and the original author. Materials, e.g. tables, taken from other sources must be accompanied by a written statement 
from both author and publisher giving permission to HPP for reproduction.  
COPYRIGHT  
Upon receipt of accepted manuscripts at Oxford Journals authors will be invited to complete an online copyright licence 
to publish form.  
 
Please note that by submitting an article for publication you confirm that you are the corresponding/submitting author 
and that Oxford University Press ("OUP") may retain your email address for the purpose of communicating with you 
about the article. You agree to notify OUP immediately if your details change. If your article is accepted for publication 
OUP will contact you using the email address you have used in the registration process. Please note that OUP does not 
retain copies of rejected articles  
 
It is a condition of publication in Health Policy and Planning that authors assign licence to publish to Oxford University 
Press. This ensures that requests from third parties to reproduce articles are handled efficiently and consistently and 
will also allow the article to be as widely disseminated as possible. In assigning licence to publish, authors may use their 
own material in other publications provided that the Journal is acknowledged as the original place of publication, and 
Oxford University Press is acknowledged as the original Publisher.  
THIRD-PARTY CONTENT IN OPEN ACCESS PAPERS  
If you will be publishing your paper under an Open Access licence but it contains material for which you do not have 
Open Access re-use permissions, please state this clearly by supplying the following credit line alongside the material:  
 
Title of content  
Author, Original publication, year of original publication, by permission of [rights holder]  
 
This image/content is not covered by the terms of the Creative Commons licence of this publication. For 
permission to reuse, please contact the rights holder.  
PRIOR PUBLICATION POLICY  
Please review our prior publication policy. We expect authors to disclose any prior dissemination including via a website 
or at national meetings. 
OFFPRINTS  
All authors are supplied with a free URL linking you to a press-ready PDF version of your article. If you wish to order 
offprints, please visit the Oxford Journals Author Services site.  
CHANGE OF ADDRESS  
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Please notify the editors of any change of address. After manuscript acceptance, please also notify the publishers: 
Journals Production Department, Oxford University Press, Great Clarendon Street, Oxford, OX2 6DP, UK. Telephone +44 
(0) 1865 556767, Fax +44 (0) 1865 267773.  
IMPORTANT NOTES TO AUTHORS  
The manuscripts will not be returned to authors following submission unless specifically requested. 
PROOFS  
Authors are sent page proofs by email. These should be checked immediately and corrections, as well as answers to any 
queries, returned to the publishers as an annotated PDF via email or fax within 3 working days (further details are 
supplied with the proof). It is the author's responsibility to check proofs thoroughly.  
PERMISSION TO REPRODUCE FIGURES AND EXTRACTS  
Permission to reproduce copyright material, for print and online publication in perpetuity, must be cleared and if 
necessary paid for by the author; this includes applications and payments to DACS, ARS and similar licensing agencies 
where appropriate. Evidence in writing that such permissions have been secured from the rights-holder must be made 
available to the editors.  
 
It is also the author's responsibility to include acknowledgements as stipulated by the particular institutions. Please 
note that obtaining copyright permission could take some time. Oxford Journals can offer information and 
documentation to assist authors in securing print and online permissions: please see the Guidelines for Authors section 
at https://academic.oup.com/journals/pages/access_purchase/rights_and_permissions.  
 
Should you require copies of this then please contact the editorial office of the journal in question or the Oxford 
Journals Rights department on journals.permissions@oup.com .  
For a copyright prose work, it is recommended that permission is obtained for the use of extracts longer than 400 
words; a series of extracts totalling more than 800 words, of which any one extract is more than 300 words; or an 
extract or series of extracts comprising one-quarter of the work or more. For poetry: an extract of more than 40 lines; 
series of extracts totalling more than 40 lines; an extract comprising one-quarter or more of a complete poem.  
 
Return to top of page. 
SUPPLEMENTARY DATA  
Supporting material that is not essential for inclusion in the full text of the manuscript, but would nevertheless benefit 
the reader, can be made available by the publisher as online-only content, linked to the online manuscript. The material 
should not be essential to understanding the conclusions of the paper but should contain data that is additional or 
complementary and directly relevant to the article content. Such information might include more detailed methods, 
extended data sets/data analysis, or additional figures. 
It is standard practice for appendices to be made available online-only as supplementary data. All text and figures must 
be provided in suitable electronic formats. All material to be considered as supplementary data must be submitted at 
the same time as the main manuscript for peer review. It cannot be altered or replaced after the paper has been 
accepted for publication and will not be edited. Please indicate clearly all material intended as supplementary data 
upon submission and name the files e.g. 'Supplementary Figure 1', 'Supplementary Data', etc. Also ensure that the 
supplementary data is referred to in the main manuscript where necessary, for example as '(see Supplementary data)' 
or '(see Supplementary Figure 1)'. 
Return to top of page. 
OXFORD OPEN ACCESS  
HPP authors have the option to publish their paper under the Oxford Open initiative; whereby, for a charge, their 
paper will be made freely available online immediately upon publication.  
 
After your manuscript is accepted the corresponding author will be required to accept a mandatory licence to publish 
agreement. As part of the licensing process you will be asked to indicate whether or not you wish to pay for open 
access. If you do not select the open access option, your paper will be published with standard subscription-based 
access and you will not be charged.  
Oxford Open articles are published under Creative Commons licences. Authors publishing in Health Policy and 
Planning can use the following Creative Commons licences for their articles:  
• Creative Commons Attribution licence (CC BY)  
• Creative Commons Non-Commercial licence (CC BY-NC)  
• Creative Commons non-Commercial No Derivatives licence (CC BY-NC-ND)  
Please click here for more information about the Creative Commons licences. 
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You can pay Open Access charges using our Author Services site. This will enable you to pay online with a credit/debit 
card or request an invoice by email or post. The open access charges applicable are:  
• Regular charge - £1680/$2678/€2205  
• Health Systems Global member charge - £1260/$2048/€1628  
• Reduced Rate Developing country charge* - £840/$1139/€1103  
• Free Developing country charge * - £0/$0/€0  
*Visit our Developing Countries page for a list of qualifying countries  
Please note that these charges are in addition to any colour/page charges that may apply. 
Orders from the UK will be subject to the current UK VAT charge. For orders from the rest of the European Union, OUP 
will assume that the service is provided for business purposes. Please provide a VAT number for yourself or your 
institution, and ensure you account for your own local VAT correctly. 
ETHICS  
Health Policy and Planning is a member of the Committee on Publication Ethics (COPE) and strives to adhere to its code 
of conduct and guidelines. 
Authors are encouraged to consult http://publicationethics.org/resources/guidelines for more information. 
In reports of investigations in humans or animals, authors must explicitly indicate (in the appropriate section of the 
Methods) their adherence to ethical standards and note the approval of an ethics committee when this is relevant. 
CROSSREF FUNDING DATA REGISTRY  
In order to meet your funding requirements authors are required to name their funding sources, or state if there are 
none, during the submission process. For further information on this process or to find out more about the CHORUS 
initiative please click here. 
 
